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Explanation of levels of evidence 
Level I  Evidence obtained from systematic review of relevant 
randomised controlled trials
Level II  Evidence obtained from one or more well designed, randomised 
controlled trials
Level III  Evidence obtained from well designed, non-randomised 
controlled trials, or from well designed cohort or case control 
studies
Level IV  Evidence obtained from case series, either post-test or pre-test 
and post-test
Level V  Opinions of respected authorities based on clinical experience, 
descriptive studies, reports of expert committees
No evidence  No evidence was found relevant to general practice on the issue 
being considered.
Source: National Health and Medical Research Council (NHMRC). A guide to the development, 
evaluation and implementation of clinical practice guidelines. Canberra: NHMRC, 1999.
Strength of recommendation
A There is good evidence to support the recommendation
B There is fair evidence to support the recommendation
C  There is poor evidence regarding the inclusion, or exclusion of the 
recommendation, but recommendations may be made on other grounds
Source: United States Preventive Services Task Force. Guide to clinical preventive services. 2nd 
edn. Baltimore: Williams and Wilkins, 1996.
Readers should note some important changes from earlier guidelines.
•   The emphasis on ‘Stages of Change’ model as an approach to smoking 
cessation has been changed because the evidence does not support the 
restriction of quitting advice and encouragement only to those smokers 
perceived to be in a stage of readiness.
•   A key message is that all people who smoke, regardless of whether they 
express a desire to stop or not, should be advised to stop smoking.
•   New data have been included about varenicline and cardiovascular disease.
•   Changes to the approved use of nicotine replacement therapy in Australia 
are included.
•   A section dealing with smoking cessation methods, which have not yet been 
researched but may prove useful, is included. 
•   The guide covers smoking cessation in high prevalence populations and in 
populations with special needs.
A summary of the evidence and recommendations is listed in Appendix 1.
Evidence for recommendations
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Introduction
Australia has made major progress in tobacco control with population 
prevalence of smoking falling substantially since the 1960s. In recent years 
smoking rates have continued to fall, including in the indigenous population 
for the first time – where rates have been unacceptably high.1,2 However, 
despite the decline in prevalence, smoking remains the behavioural risk factor 
responsible for the highest levels of preventable disease and premature death.3 
The task of further reducing the number of Australians who are using tobacco 
requires a collaborative effort between government, health authorities, health 
professionals and the community at large. 
The former chief adviser to the Australian Government on tobacco control, 
Professor David Hill, has likened tobacco control efforts to keeping a spring 
compressed – take the pressure off and rates of tobacco use, and the harm 
that follows, will rebound. Tobacco control involves preventing uptake and 
supporting cessation. Health professionals play a key role in both, but have 
a particular responsibility to assist all smokers to stop.4,5 Reducing parental 
smoking rates is the intervention with the clearest effect on youth smoking 
uptake. 
Two publications, Smoking cessation guidelines for Australian general 
practice (2004)6 and Smoking cessation pharmacotherapy: an update for 
health professionals (2009),7 provided a framework for assisting quitting, and 
informed health professionals of developments in the understanding of nicotine 
addiction and the pharmacotherapies available to assist smoking cessation. 
These publications were based on a literature review undertaken for the 
National Tobacco Strategy,8 experience with cessation programs in Australia 
– in particular the Smokescreen Program9 – and international experience with 
smoking cessation guidelines in other countries.10–13 
Since these publications, there have been important developments in both 
the science and practice of cessation support. These include advances in 
our understanding of the neurobiology of nicotine addiction, further research 
on the use of varenicline and substantial changes in the approved use of 
nicotine replacement therapy (NRT). Another important development for 
smoking cessation in Australia has been the listing of nicotine patches on 
the Pharmaceutical Benefits Scheme, initially for Aboriginal and Torres Strait 
Islander people in 2008, and for the general community since February 2011. 
Supporting smoking cessation: a guide for health professionals aims to be a 
practical, succinct and evidence based resource that can be used by a wide 
range of health professionals working in a variety of contexts. As with the 
previous publications, it is based on research evidence and is informed by 
guidelines from other countries with similar population profiles. It seeks to link 
smoking cessation advice by health professionals to the materials and support 
services provided through the telephone quitlines operating in each state and 
territory. It also seeks to build on the momentum for cessation gained by public 
health interventions such as tax increases, restrictions on smoking in public 
places, changes to tobacco display and packaging and the social marketing of 
smoking cessation. 
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Tobacco smoking is a worldwide threat to human life. The World Health 
Organization (WHO) estimates that around 5.4 million people died prematurely 
in 2008 from tobacco related diseases and, on current trends, this number 
will increase to 8 million deaths each year before 2030. Eighty percent of 
these deaths will occur among people in the developing world.14 Fortunately, in 
Australia the prevalence of tobacco smoking has decreased. The proportion 
of people aged 14 years and over smoking tobacco daily in 2010 was 15.1%, 
down 16.6% from 3 years previously.1 While rates remain much higher in the 
indigenous population than in the rest of the Australian population, the first 
statistically significant decline in smoking rates for Indigenous Australians was 
seen between 2002 and 2008, from 53% to about 50% respectively.2
Australia is a signatory to the WHO Framework Convention on Tobacco Control, 
a worldwide effort to control the effects of tobacco smoking on human health.15 
The framework is the world’s first public health treaty and commits governments 
to enacting a minimum set of policies, which are proved to curb tobacco use. 
These include bans on tobacco advertising, promotion and sponsorship, 
clear warning labels, smoke free policies, higher prices and taxes on tobacco 
products and access to, and availability of, smoking cessation services. It also 
encourages international cooperation in dealing with cigarette smuggling and 
cross border advertising.
As a result of changes in public policy and changing community attitudes to 
tobacco, the status of tobacco smoking is gradually shifting from a socially 
acceptable behaviour to an antisocial one.16 With the advent of national tobacco 
control policies and programs, the prevalence of smoking in Australia is among 
the lowest of any nation.17 While Australia’s level of smoking continues to fall 
and is the third lowest for OECD (Organisation for Economic Cooperation and 
Development) countries,18 Indigenous Australians are still more than twice as 
likely as non-Indigenous Australians to be current daily smokers.2 
The importance of smoking cessation was reinforced in the report of the 
National Preventative Health Taskforce, which stated that the evidence for 
interventions to reduce smoking is strong and has accumulated over many 
years. The report made several key recommendations on improving advice 
from health professionals, including ensuring all smokers in contact with health 
services are routinely asked about their smoking status and supported to quit.19 
National Preventative Health Taskforce.  
Key action area 6: Tobacco control19 
Ensure all smokers in contact with health services are encouraged and 
supported to quit, with particular efforts to reach pregnant women and those 
with chronic health problems.
Ensure all state or territory funded healthcare services (general, maternity and 
psychiatric) are smoke free and protecting staff, patients and visitors from 
exposure to secondhand smoke, both indoors and on facility grounds.
Tobacco smoking: the scope of the problem 
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Nevertheless, smoking still causes a higher burden of disease than any other 
behavioural risk factor, representing 9.6% of the total burden in men and 5.8% 
in women.20 Tobacco smoking is responsible for the deaths of about 15 500 
Australians each year (Table 1).21
Table 1. Deaths attributable to tobacco by specific cause, 
Australia, 2003 (burden of disease calculations)20
Specific cause Number of deaths Percentage of all  tobacco 
caused  deaths (rounded)*
Lung cancer 6309 41
COPD 4175 27
CHD 1962 13
Stroke 577 4
Oesophageal cancer 572 4
Other 1916 12
Total 15 511  
* Column does not add up to 100% due to rounding
Interventions to assist cessation are in the context of a changing environment: 
the low community tolerance for tobacco smoking is one sign of a continuing 
‘denormalisation’ of tobacco use in Australia.22 
Tobacco smoking harms almost every organ of the body, causing a wide range 
of diseases and harming the health of smokers (Table 2).23 
Smoking is strongly related to many chronic diseases including coronary heart 
disease, stroke, chronic obstructive pulmonary disease, asthma, rheumatoid 
arthritis and osteoporosis,18 and is responsible for 20% of all cancer deaths in 
Australia.24 Smoking also has adverse effects in pregnancy, both for the mother 
and the developing fetus, and exposure to secondhand tobacco smoke has 
been shown to damage the health of children and adults. The only proven 
strategy for reducing the risk of tobacco related diseases and death is to avoid 
taking up smoking and, failing that, to quit as early as possible in adult life.23 
Quitting smoking has immediate, as well as long term benefits, reducing the 
risks for diseases caused by smoking and improving health in general.
Reprinted with permission: Scollo MM, Winstanley MH, editors. Tobacco in Australia: Facts and Issues. 3rd 
edn. Melbourne: Cancer Council Victoria; 2008. Available from www.tobaccoinaustralia.org.au
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Table 2. Health effects of smoking
Eyes
Macular degeneration
Stomach
Cancer, ulcer
Hair 
Hair loss
Pancreas
Cancer
Skin
Ageing, wrinkles, wound infection
Bladder
Cancer
Brain
Stroke
Women
Cervical cancer, early menopause, 
irregular and painful periods
Mouth and pharynx
Cancer, gum disease
Men
Impotence
Lungs
Cancer, emphysema, pneumonia
Arteries
Peripheral vascular disease
Heart
Coronary artery disease
Bones
Osteoporosis
Key findings from the 2010 National Drug Strategy Household 
Survey report1
•  15.1% of people in Australia, aged 14 years or older, were daily smokers. 
This declined from 16.6% in 2007, and from 24.3% in 1991 
•  One-quarter of the population were ex-smokers and more than half had 
never smoked
•  Tobacco smoking (smoked in the previous 12 months) remains higher 
among certain populations, such as those with the lowest socioeconomic 
status (24.6%) and those living in remote areas (28.9%) 
•  Indigenous Australians were 2.2 times as likely as non-Indigenous 
Australians to smoke tobacco
• Compared with non-smokers (ex-smokers and those who never smoked), 
smokers were more likely to rate their health as being fair or poor, were 
more likely to have asthma, were twice as likely to have been diagnosed or 
treated for a mental illness and were more likely to report high or very high 
levels of psychological distress in the preceding 4 week period 
• A higher proportion of smokers reported being diagnosed, or treated for a 
mental illness in 2010 (from 17.2% in 2007 to 19.4%)
• Almost 40% of smokers had reduced the amount they smoked in a day, 
and 29% had tried unsuccessfully to give up smoking 
• The proportion of people nominating cost as a factor for wanting to quit 
smoking increased significantly from 35.8% in 2007 to 44.1% in 2010.
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Effectiveness of treating tobacco dependence
The benefits of quitting smoking are well established. Successfully quitting 
smoking can result in an increase in life expectancy of up to 10 years, if it 
occurs early enough.25 There is also substantial evidence that advice from 
health professionals including doctors, nurses, pharmacists, psychologists, 
dentists, social workers and smoking cessation specialists helps smokers to 
quit.26–29 While spending more time (longer than 10 minutes) advising smokers to 
quit yields higher abstinence rates than minimal advice,10 offering brief advice (as 
little as 3 minutes) has been shown to have clear benefits.26,30,31 Providing brief 
advice to most smokers is more effective and efficient than spending a longer 
time with a few patients.30,32
Smoking cessation is both cost and clinically effective compared with 
other medical and disease preventive measures, such as the treatment of 
hypertension and hypercholesterolaemia.33–36 Research shows that the cost 
per life year saved by smoking cessation interventions makes it one of the most 
cost-effective healthcare interventions.37,38 Along with childhood immunisation 
and aspirin use with high risk adults, overall efforts to reduce tobacco smoking 
are among the most beneficial preventive interventions for human health.37,39,40
Advice based help and pharmacotherapy can both increase the rate of success 
of quit attempts, and when they are used the benefits are cumulative.10 Smokers 
should be offered cessation treatment, either counselling (individual or group) 
or medication, or both, which is individualised and customised to their own 
personal situation and experience.
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Smoking cessation advice and support from health professionals are key 
aspects of a comprehensive approach to tobacco control. Health professionals 
can make an important contribution to tobacco control in Australia and to 
the health of the community by providing opportunities for smokers to quit. 
An encouraging environment can be provided in health settings (primary and 
community care, hospitals, dental, eye care and pharmacies)5,7,26–29,41 and in 
non-health settings (workplaces, prisons, schools, state housing, social welfare 
services).42,43 All types of health professionals can play an important role – WHO 
states that involvement in offering smokers advice and assistance with quitting 
should be based on factors such as access, rather than professional discipline.12 
Health professionals play an important role in educating and motivating smokers 
as well as assessing their dependence on nicotine and providing assistance 
to quit. All health professionals should systematically identify smokers, 
assess their smoking status and offer them advice and cessation treatment 
at every opportunity.26–29,44 Where a client presents with a problem caused or 
exacerbated by smoking, it is of vital importance for health professionals to raise 
the issue of smoking cessation.
There is a range of evidence based strategies that can improve the 
implementation of effective smoking cessation intervention in the practice 
setting.45–48 Providing a systematic approach to smoking cessation is associated 
with higher levels of success.10 Routine enquiry through waiting room surveys47,49 
or use of additional practice staff to provide counselling, is associated with 
higher quit rates.29 Where health professionals are not able to offer support 
or treatment within their own practices, they should refer smokers for help 
elsewhere – for example, to Quitline and local programs that may be available in 
each state such as the Fresh Start course by Quit Victoria.50
Brief interventions for smoking cessation involve opportunistic advice, 
encouragement and referral. Interventions should include one or more of the 
following:6,10,51
• brief advice to stop smoking
• an assessment of the smoker’s interest in quitting
• an offer of pharmacotherapy and counselling where appropriate
• providing self help material 
• referral to more intensive support such as Quitline (see Appendix 2) and other 
local programs that may be available in each state.
The role of health professionals
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Beliefs that can be barriers to optimal smoking cessation advice
Asking about smoking and offering advice and assistance are key roles for  
health professionals. Barriers raised by health professionals to engaging in  
greater efforts to provide smoking cessation advice include: 
• a perception that it is ineffective
• lack of time
• lack of smoking cessation skills
• reluctance to raise the issue due to perceived patient sensitivity about smoking
• perceived lack of patient motivation.52,53 
Table 3 presents evidence in relation to these barriers.
Table 3. Barriers to smoking cessation
Belief Evidence
Assistance with smoking 
cessation is not part of my role
Most patients think smoking cessation 
assistance is part of your clinical role44,54
I have counselled all my smokers Only 45–71% of smokers are counselled55,56
Smokers aren’t interested in 
quitting
Nearly all smokers are interested in quitting 
although some are temporarily put off by past 
failures. More than 40% of smokers make quit 
attempts each year and more think about it57
I routinely refer patients for 
smoking cessation assistance
Referrals to Quitline are low (10–25%)58
I’m not effective Clinicians can achieve substantial quit rates 
over 6–12 months, 12–25% abstinence, which 
have important public health benefits26,44,50
Smokers will be offended by 
enquiry
Visit satisfaction is higher when smoking is 
addressed appropriately56,59
I don’t have time to counsel 
smokers
Effective counselling can take as little as a 
minute10
Evidence
Smoking cessation advice from health professionals is effective in increasing 
quit rates. The major effect is to help motivate a quit attempt. Level I. All health 
professionals can be effective in providing smoking cessation advice. Level I
Recommendation
All smokers should be offered brief advice to quit. Strength A
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Tobacco dependence is a chronic condition that typically requires repeated cessation 
treatment and ongoing care.10,60 A minority of smokers achieve long term abstinence 
on the first attempt to quit, while the majority cycle through multiple attempts with 
relapse and remission before achieving long term, or permanent abstinence. Multiple 
attempts over a period of years are not unusual.
It is important to take every opportunity to identify all smokers, document their 
smoking status and offer treatment, which may involve counselling by a health 
professional, referral to more intensive support and pharmacotherapy.
Research shows that the most common method used by most people who have 
successfully stopped smoking is unassisted cessation (either stopping abruptly or 
cutting down on their own),61 although now more than half of all smokers making quit 
attempts are using some form of help, mainly medications.62 If smokers want to try to 
quit unassisted they should be encouraged to do so, but told that support is available 
should they want it. Many smokers need encouragement, assistance and guidance 
to quit successfully. Smokers who are more nicotine dependent are more likely to 
seek treatment.63 
There are two ways to increase the number of people successfully quitting: improve 
the success rate and/or increase the number of attempts. Given the costs and limited 
achievement in improving success rates, increasing the number of attempts to quit 
remains the most important strategy for improving cessation rates in the population.64 
Health professionals are the key to increasing the frequency of quit attempts by 
encouraging smokers to keep trying. Smokers should be aware that it is normal to 
make multiple attempts, and that many of those who have succeeded in quitting 
have had this same experience.65 Health professionals can increase the chances of 
success by encouraging use of the most effective strategies.
Ask, assess, advise, assist and arrange follow up
The 5As approach (five components of effective tobacco cessation counselling) 
originally proposed by the US Clinical Practice Guideline,10 provides health 
professionals with an evidence based framework for structuring smoking cessation 
by identifying all smokers and offering support to help them quit.6,7 The approach is 
adopted in guidelines from The Netherlands and WHO,11,12 and adopted in modified 
forms in other international guidelines.13,51 
The 5As structure allows health professionals to provide the appropriate support 
for each smoker’s level of interest in quitting (Figure 1). Where possible, health 
professionals should maintain long term and ongoing relationships with smokers, in 
order to foster the person’s motivation and confidence to attempt smoking cessation. 
It is important for health professionals to ask all patients/clients if they use tobacco, 
assess their willingness to make a quit attempt, advise on the importance of quitting 
and offer assistance in the form of help from the health professional or referral.  
The 5As structure for smoking cessation
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Assess
Advise
Assist – not ready
Arrange follow up
Assist – unsure Assist – ready
A
s
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A
R
R
A
N
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O
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O
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•	 Assess	stage	of	change:	
  ‘How do you feel about your 
smoking	at	the	moment?’	
and ‘Are you ready to stop 
smoking	now?’
•	 Record	stage	of	change
•	 Assess	nicotine	dependence
All	smokers	should	be	advised	to	quit	in	a	way	that	is	clear	but	nonconfrontational
eg.	‘The	best	thing	you	can	do	for	your	health	is	to	quit	smoking’
•	 	Discuss	the	benefits	
of	quitting	and	risks	
of	continued	smoking
•	 	Provide	information	
about not exposing 
others	to	passive	
smoking
•	 	Advise	that	help	is	
available	when	they’re	
ready
•	 	For	clients	attempting	to	quit,	arrange	follow	up	visit,	
if possible
•	 At	these	visits:
	 –	congratulate	and	affirm	decision
 – review progress and problems
	 –	encourage	continuance	of	pharmacotherapy
	 –	discuss	relapse	prevention
	 –	encourage	use	of	support	services
OR
•	 Refer	to	Quitine 13 7848
•	 	Do	motivational	
interviewing:	‘What	
are	the	things	you	like	
and	don’t	like	about	
your	smoking?’
•	 Explore	their	doubts
•	 	Explore	barriers	to	
quitting
•	 	Offer	written	
information (eg. Quit 
Pack)	and	referral	to	
Quitline 13 7848
•	 	Affirm	and	encourage
•	 	Provide	a	Quit	Pack	
and	discuss	a	quit	
plan
•	 	Recommend	
pharmacotherapy	to	
nicotine	dependent	
smokers (see Assess)
•	 	Discuss	relapse	
prevention
•	 	Offer	referral	to	
Quitline 13 7848
Assess	nicotine	dependence
•	 Nicotine	dependence	can	be	assessed	by	asking:
	 1.	‘How	many	minutes	after	waking	to	first	cigarette?’
	 2.	‘Number	of	cigarettes	per	day?’
	 3.	‘What	cravings	or	withdrawal	symptoms	in	previous	quit	attempts?’
•	 	Smoking	within	30	minutes	of	waking,	smoking	more	than	10	cigarettes	
per	day	and	history	of	withdrawal	symptoms	in	previous	quit	attempts	
are	all	markers	of	nicotine	dependence
•	 	Pharmacotherapy	for	dependent	smokers	is	proven	to	double	the	
chances	of	successfully	quitting
Assist	–	action	and	
maintenance
•	 Congratulate
•	 	Discuss	relapse	
prevention
•	 	Review	and	reinforce	
benefits	of	quitting
•	 	Offer	written	
information (eg. Quit 
Pack)	and	referral	to	
Quitline 13 7848
Successful	quitter
•	 	Congratulate	and	
affirm	decision	to	quit
•	 	Discuss	relapse	
prevention
•	 	Offer	ongoing	
encouragement	for	
at least 5 years after 
quitting
Relapse
•	 	Offer	support	and	
reframe as a learning 
experience
•	 	Explore	reasons	for	
relapse and lessons 
for	future	quit	
attempts
•	 	Offer	ongoing	
support
•	 	Ask	again	at	future	
consultations
Yes
Ask all patients
Do	you	still	smoke	tobacco?				
•	 Record	smoking	status
(current	smoker)
Ask all patients
Check	every	5	years,	or	more	frequently	 
if under 25 year of age or an ex-smoker
•	 	Affirm	decision	to	quit	and	record	smoking	status	(ex-smoker)
•	 	Give	relapse	prevention	advice	if	quit	<1	year
•	 	Ongoing	encouragement	up	to	at	least	5	years	quit
•	 	Affirm	choice	not	to	smoke	 
and	record	smoking	status
	 (never	smoker)
Yes
No No
Figure 1. The 5As structure for health professionals for smoking cessation
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1. Ask all patients about smoking
Ask all patients
Ask
Do you still smoke tobacco?    
•	 Record	smoking	status
(current	smoker)
Ask all patients
Check	every	5	years,	or	more	frequently	 
if	under	25	year	of	age	or	an	ex-smoker
•	 	Affirm	decision	to	quit	and	record	smoking	status	(ex-smoker)
•	 	Give	relapse	prevention	advice	if	quit	<1	year
•	 	Ongoing	encouragement	up	to	at	least	5	years	quit
•	 	Affirm	choice	not	to	smoke	 
and	record	smoking	status
	 (never	smoker)
Yes
Yes
No No
Health professionals should ask all their patients/clients whether they smoke 
and their smoking status should be recorded. Implementing recording systems 
that document tobacco use almost doubles the rate at which clinicians 
intervene with smokers and results in higher rates of smoking cessation.10 
Evidence
Instituting a system designed to identify and document tobacco use 
almost doubles the rate of health professional intervention and results in 
higher rates of cessation. Level II
Recommendation
A system for identifying all smokers and documenting tobacco use 
should be used in every practice or healthcare service. Strength A
2. Assess readiness to quit
ASSESS
Assess
•	 Assess	stage	of	change:	
	 	‘How	do	you	feel	about	your	
smoking	at	the	moment?’	
and	‘Are	you	ready	to	stop	
smoking	now?’
•	 Record	stage	of	change
•	 Assess	nicotine	dependence
Assess	nicotine	dependence
•	 Nicotine	dependence	can	be	assessed	by	asking:
	 1.	‘How	many	minutes	after	waking	to	first	cigarette?’
	 2.	‘Number	of	cigarettes	per	day?’
	 3.	‘What	cravings	or	withdrawal	symptoms	in	previous	quit	attempts?’
•	 	Smoking	within	30	minutes	of	waking,	smoking	more	than	10	cigarettes	per	
day	and	history	of	withdrawal	symptoms	in	previous	quit	attempts	are	all	
markers	of	nicotine	dependence
•	 	Pharmacotherapy	for	dependent	smokers	is	proven	to	double	the	chances	
of	successfully	quitting
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Assessment of readiness to quit
Prochaska and DiClemente’s Stages of Change Model66 acknowledges that the 
smoker’s level of motivation is an important issue in cessation and advice can 
be  tailored on the basis of a smokers’ readiness to quit.6 
The role of Stages of Change Model to assisting smoking 
cessation
• The model serves as a reminder that people at all stages can be offered 
assistance 
• Smokers do not necessarily progress through each of the stages of change 
before attempting to quit, but the model can help clinicians tailor advice in a 
way that is most applicable to the smoker at that encounter
• Smokers are in different stages of readiness when the clinician sees them at 
different times, so readiness needs to be re-evaluated at every opportunity. 
The extent of the assessment will depend on the clinical context
• Stages of change can be influenced by the nature of the communication 
and the relationship between health professional and smoker.67
Though there is a lack of evidence for greater effectiveness of stage based 
approaches,68 this model provides a useful framework to help clinicians identify 
smokers and provide tailored support for a smoker’s level of interest in quitting 
in a way that is time efficient and likely to be well received.9,69
There is some evidence that the likelihood of success in an attempt to quit is 
unrelated to the smoker’s expressed interest in quitting in the period leading up 
to the attempt – unplanned attempts to quit are as likely (or even more likely) to 
be as successful as planned attempts.70,71 Thus, there is benefit in encouraging 
all smokers to consider quitting whenever the opportunity arises.10 
Evidence
Factors consistently associated with higher abstinence rates are high 
motivation, readiness to quit, moderate to high self-efficacy and supportive 
social networks. Level III
Recommendation
Assessment of readiness to quit is a valuable step in planning treatment. 
Strength C
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Assessment of nicotine dependence
Most smokers become nicotine dependent – dependence can happen quickly 
and, in some cases, even after a few cigarettes. As nicotine addiction is 
under-recognised by clinicians, routine assessment of nicotine dependence 
can help predict whether a smoker is likely to experience nicotine withdrawal 
upon stopping smoking,72,73 and the intensity and type of support that may be 
required to assist quitting.
Nicotine withdrawal symptoms commonly include craving, as well as onset of 
any of the following shortly after stopping:
• depressed mood
• insomnia
• irritability, frustration, anger
• anxiety
• difficulty in concentration
• restlessness
• mouth ulcers
• constipation
• increased appetite or weight gain.
Characteristics of smokers with nicotine dependence include smoking soon 
after waking, smoking when ill, difficulty stopping smoking, finding the first 
cigarette of the day the most difficult to give up, and smoking more in the 
morning than in the afternoon.72,74,75
A quick assessment of nicotine dependence can be made by asking the 
smoker:
• ‘How soon after waking do you have your first cigarette?’
• ‘How many cigarettes do you smoke each day?’
• ‘Have you had cravings for a cigarette, or urges to smoke and withdrawal 
symptoms when you have tried to quit?’
Smoking within 30 minutes of waking, smoking more than 10 cigarettes per day 
(although some dependent smokers may not be daily smokers) and a history of 
withdrawal symptoms in previous attempts to quit are all indicators of nicotine 
dependence. Time to first cigarette has been shown to be a reliable indicator of 
nicotine dependence.
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3. Advise all smokers to quit
ADVISE 
Advise
All smokers should be advised to quit in a way that is clear but nonconfrontational
eg. ‘The best thing you can do for your health is to quit smoking’
Brief, repeated, consistent, positive reminders to quit and reinforcing recent quit 
efforts by a number of health professionals can increase success rates. When 
the practice is routinely applied to a large proportion of clients who smoke, 
a larger impact on population smoking rates can be achieved.10 Establishing 
rapport and asking permission minimises any risk of harming the patient-health 
professional relationship. In fact, asking if smokers would like to have help to 
quit can be appreciated and can strengthen the relationship.76 Where possible, 
it helps to personalise the advice and the benefits of quitting. Patients express 
greater visit satisfaction when smoking cessation is addressed.59,77 One useful 
approach to raising the topic is to acknowledge that the smoker is aware of the 
risks, and ask if he or she is ready to discuss options.
Evidence
Brief smoking cessation advice from health professionals delivered 
opportunistically during routine consultations has a modest effect size, but 
substantial potential public health benefit. Level I
Recommendation
Offer brief cessation advice in routine consultations and appointments 
whenever possible (at least annually). Strength A
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4. Assist
ASSIST
Assist – not ready Assist – unsure Assist – ready
•	 	Discuss	the	benefits	
of quitting and risks 
of	continued	smoking
•	 	Provide	information	
about	not	exposing	
others	to	passive	
smoking
•	 	Advise	that	help	is	
available	when	they’re	
ready
•	 	Do	motivational	
interviewing:	‘What	
are	the	things	you	like	
and	don’t	like	about	
your	smoking?’
•	 Explore	their	doubts
•	 	Explore	barriers	to	
quitting
•	 	Offer	written	
information	(eg.	Quit	
Pack)	and	referral	to	
Quitline	13	7848
•	 	Affirm	and	encourage
•	 	Provide	a	Quit	Pack	
and	discuss	a	quit	
plan
•	 	Recommend	
pharmacotherapy	to	
nicotine	dependent	
smokers	(see	Assess)
•	 	Discuss	relapse	
prevention
•	 	Offer	referral	to	
Quitline	13	7848
Assist	–	action	and	
maintenance
•	 Congratulate
•	 	Discuss	relapse	
prevention
•	 	Review	and	reinforce	
benefits	of	quitting
•	 	Offer	written	
information	(eg.	Quit	
Pack)	and	referral	to	
Quitline	13	7848
The decision on whether and what assistance to provide to smokers and 
recent quitters depends on their needs, preferences and suitability for available 
support, and the capacity of the health professional and their service. A 
package of assistance can be put together, which may involve the health 
professional and their service, or referral or a combination of these options. 
When necessary, clients should be referred to a health professional with 
a smoking cessation practice, or to a tobacco treatment specialist where 
medication can be prescribed where indicated. 
Assistance from the health professional may involve motivational interviewing. 
This is a counselling technique based on a therapeutic partnership that 
acknowledges and explores a client’s ambivalence about a behaviour. 
Motivational interviewing is a counselling philosophy that values patient 
autonomy and mutual respect and the use of open-ended questions, 
affirmations, reflection and summarising.78 
Motivational interviewing
This type of counselling requires more time available than brief interventions. It 
is a proven counselling technique to help explore a client’s ambivalence about 
their behaviour (eg. smoking).79 
Motivational interviewing is a directive, non-confrontational, client centred 
counselling strategy aimed at increasing a person’s motivation to change. It is 
a counselling style based on collaboration rather than confrontation, evocation 
rather than education and autonomy instead of authority – as opposed to a set 
of techniques.
16 Healthy Profession. Healthy Australia.
The RACGP 
Supporting smoking cessation: a guide for health professionals
Barriers to quitting
It is important for health professionals to be aware of the potential difficulties 
smokers face when attempting to quit and, where possible, to address the 
barriers at the time of the quit attempt. This could include providing treatment 
for withdrawal symptoms or mental health issues, or recommending physical 
activity and a healthy diet to minimise weight gain. Situations likely to lead to 
unsuccessful attempts at quitting include:16,53
• lack of knowledge of the benefits of quitting 
• high dependence on nicotine and heavy smoking (more than 20 cigarettes 
per day, time to first cigarette)
• enjoyment of nicotine or smoking behaviour
• psychological or emotional concerns (stress, depression, anxiety, psychiatric 
disorders)
• fear of weight gain
• substance use (alcohol and other drugs)
• living with other smokers 
• peer pressure, social smoking
• circumstances that result in the smoker giving quitting a low priority such 
as poverty, social isolation and how ‘normal’ smoking is regarded in the 
smoker’s social circles.
Belief Strategy to counteract the belief80–82
I can quit at any time/I’m not addicted Ask about previous quit attempts and 
success rates
Use of cessation assistance is a sign of 
weakness/help is not necessary
Reframe assistance
Highlight unassisted quit rate is 3–5%
Too addicted/too hard to quit Ask about previous quit attempts
Explore pharmacotherapy used and offer 
options, eg. combination therapy
Too late to quit/I might not benefit so 
why bother
Benefits accrue at all ages, and are greater if 
earlier: at age 30 years, similar life expectancy 
to non-smoker. Provide evidence/feedback, 
eg. spirometry, absolute risk score
My health has not been affected by 
smoking/you have to die of something/I 
know a heavy smoker who has lived a 
long time
Provide evidence/feedback, eg. spirometry, 
absolute risk score
Reframe, eg. chronic obstructive pulmonary 
disease (COPD) = smoker’s lung
Not enough willpower/no point in trying 
unless you want to/to quit successfully 
you really have to want to, then you will 
just do it
Explore motivation and confidence. Explore 
and encourage use of effective strategies, eg. 
Quitline, pharmacotherapy
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Smokers should be reassured that it may take many attempts at quitting (more 
than 8–14 times) before successfully stopping, but that this should not stop them 
attempting. They can also learn something from each attempt to help overcome 
tobacco dependence.
5. Arrange follow up
ARRANGE FOLLOW UP
Arrange follow up
•	 	For	clients	attempting	to	quit,	arrange	follow	up	visit,	
if	possible
•	 At	these	visits:
	 –	congratulate	and	affirm	decision
	 –	review	progress	and	problems
	 –	encourage	continuance	of	pharmacotherapy
	 –	discuss	relapse	prevention
	 –	encourage	use	of	support	services
OR
•	 Refer	to	Quitine	13	7848
Successful	quitter
•	 	Congratulate	and	
affirm	decision	to	quit
•	 	Discuss	relapse	
prevention
•	 	Offer	ongoing	
encouragement	for	
at	least	5	years	after	
quitting
Relapse
•	 	Offer	support	and	
reframe	as	a	learning	
experience
•	 	Explore	reasons	for	
relapse	and	lessons	
for	future	quit	
attempts
•	 	Offer	ongoing	
support
•	 	Ask	again	at	future	
consultations
Follow up visits to discuss progress and to provide support have been shown to 
increase the likelihood of successful long term abstinence.44,83 
Relapse prevention includes awareness of coping strategies for high risk situations 
such as stress, negative emotional states, alcohol and other social cues to smoke. It is 
important to frame each lapse (a single smoke), or full relapse to smoking as a learning 
experience and encourage the smoker to try again with support in the future.
All interventions by a health professional, or by a team of health professionals, should 
be recorded so that progress in quitting can be monitored and adjustments made 
where and when necessary to current medications, cessation pharmacotherapy and 
intensive counselling.
Evidence
Follow up is effective in increasing quit rates. Level I
Recommendation
All smokers attempting to quit should be offered follow up. Strength A
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Nicotine addiction
Almost 25 years ago, the US Surgeon General’s report, The Health 
Consequences of Nicotine Addiction, concluded that nicotine was the drug in 
tobacco that caused addiction.23 Many international medical authorities, including 
WHO, have confirmed the findings that tobacco products are highly addictive.84 
Of all people who commence tobacco use, almost one third (32%) become 
addicted smokers.16 Dependence on nicotine develops quickly. Studies show that 
non-daily tobacco use triggers the emergence of nicotine dependence – in the 
second Development and Assessment of Nicotine Dependence in Youth study, 
where subjects had smoked at least one cigarette, 62% smoked at least once 
per month, 53% experienced dependence symptoms and 40% experienced 
escalation to daily smoking.85 Dependence would not occur without nicotine, but 
nicotine is not responsible for the harmful effects of smoking, which are caused 
mainly by tar, oxidising chemicals, carbon monoxide and other constituents of 
tobacco or tobacco smoke.16,23,84 
Dependence on smoking is a complex process. It requires a close link in time 
between the context in which smoking occurs, its rituals, the sensory stimuli of 
touch, taste and smell, and the extremely rapid delivery of nicotine to the brain that 
occurs when smoking a modern cigarette. Evidence suggests that psychosocial, 
biological and genetic factors all play a role in nicotine addiction.23,84,89  
Greater understanding of the neurobiology of nicotine dependence is improving 
the use of existing cessation therapies and is helping to develop new compounds 
to aid smoking cessation. When cigarette smoke is inhaled, the large surface area 
of the lungs means that nicotine is rapidly absorbed into the pulmonary venous 
circulation and travels quickly to the brain through the bloodstream.86 Nicotine is 
active within the brain reward system within seconds of inhalation.87 The addictive 
components of tobacco products affect multiple types of nicotine receptors in 
the brain including, but not confined to, the α4β2 nicotinic acetylcholine receptor. 
Activation of this and other receptors triggers the release of dopamine and other 
neurotransmitters. This reward system is the common pathway for the experience 
of pleasure from many different social, physical and chemical stimulants, including 
other drugs of addiction such as cocaine and opiates. As well as the activation 
of the reward system, the negative effects of nicotine withdrawal are important 
factors in the continuation of smoking. 
Genetic factors play a role in the differing patterns of smoking behaviour and 
smoking cessation. The degree of susceptibility to developing tobacco addiction 
– as well as the ease or difficulty of quitting and sustaining abstinence – has 
been reported from twin and adoption studies. This research shows a high 
degree of heritability of cigarette smoking (50–70%).88,89 The finding points to an 
understanding of why smokers vary widely in their relationship to tobacco and their 
ability to quit. However, a useful way to target treatment based on genetics has not 
yet been shown. The studies also indicate that there may be some smokers who 
never fully overcome their addiction, or who can never quit all nicotine use.84
The most immediate benefit of research into the genetics of smoking is the 
development of effective drugs to assist smokers to stop smoking. It might also 
allow better matching of smokers to cessation treatments.90
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Three forms of medicine (nicotine replacement therapy, varenicline and bupropion) are 
licensed and available in Australia to assist smoking cessation. These medicines have been 
shown to assist smoking cessation in meta-analyses of randomised clinical trials.91–94
Pharmacotherapy is recommended for all dependent smokers who express an interest 
in quitting, except where contraindicated.6,10 Smokers who want to try unassisted quitting 
should be encouraged to do so. However, best results are achieved when medicines are 
used in combination with counselling and support,61,63 although there is some evidence that 
nicotine replacement therapy (NRT) can increase quit rates with or without counselling.93 
The choice of pharmacotherapy is based on clinical suitability and patient choice (Figure 2 ).
TreaTmenT algoriThm
Assess nicotine dependence
nicotine dependence can be briefly assessed by asking:
•	 Minutes	after	waking	to	first	cigarette?
•	 Number	of	cigarettes	per	day?
•	 Cravings	or	withdrawal	symptoms	in	previous	quit	attempts?
Indication of nicotine dependence
•	 Smoking	within	30	minutes	of	waking
•	 Smoking	more	than	10	cigarettes	per	day
•	 History	of	withdrawal	symptoms	in	previous	quit	attempts.
Also	consider	patient’s	previous	experience	and	views	on	pharmacotherapy.
•	 	Recommend	use	of	pharmacotherapy	to	increase	chance	 
of	successful	cessation
•	 	Explain	options	for	pharmacotherapy	(nicotine	replacement	
therapy,	varenicline,	bupropion)
•	 	Specify	therapy	based	on	clinical	suitability	and	patient	
preference
•	 	Explain	that	medicines	can	reduce	felt	needs	to	smoke,	but	
do	not	eliminate	them;	they	are	only	aids	to	quitting
•	 	Provide	counselling	in	combination	with	pharmacotherapy.
Support	quit	attempt	with	nonpharmacological	strategies
•	 Counselling
•	 	Cognitive	and	behavioural	coping	strategies:	delay,	
deep	breathe,	drink	water,	do	something	else
•	 Offer	written	information	(eg.	Quit	Pack)
•	 Offer	Quitline	referral	or	other	assistance
•	 Arrange	follow	up	visit,	if	appropriate
Not	willing	to	use	
pharmacotherapy
not nicotine dependent
Assessment	for	need	for	pharmacotherapy
Nicotine	dependent:	pharmacotherapy Nonpharmacological	support
Nicotine	replacement	therapy	(NRT) Varenicline Bupropion	sustained	release
Clinical suitability
Can	be	used	in	all	groups	of	smokers	
including	adolescents.	Use	with	caution	in	
pregnant	women	and	patients	with	unstable	
cardiovascular	disease	(check	PI)
Patient choice
Reasons	to	prefer:
•	 	OTC	availability	(all	forms)	and	also	PBS	
subsidy	(patch)
•	 	concerns	about	side	effects	of	varenicline	and	
bupropion
•	 	can	be	used	in	pregnancy	under	medical	
supervision
•	 variety	of	dosage	forms	available.
•	 	Discuss	benefit	of	follow	up	visits,	especially	
if	there	are	concerns	about	side	effects,	eg.	
skin	irritation,	sleep	disturbance
•	 	Encourage	use	of	support	services
•	 	Encourage	completion	of	at	least	10	weeks	
of	therapy
•	 	Consider	combination	NRT	if	withdrawal	not	
controlled
•	 	Consider	a	further	follow	up	visit	if	patient	
needs	extra	support.
Clinical suitability
Not	recommended	in	pregnancy	and	
childhood.	Caution	with	significant	intercurrent	
psychological/psychiatric	disease.	Caution	
in	cardiovascular	disease.	Nausea	in	30%	
of	patients.	Reduce	dose	in	severe	renal	
impairment	(check	PI)
Patient choice
Reasons	to	prefer:
•	 	on	current	evidence,	vareniciline	is	the	most	
effective	pharmacotherapy
•	 PBS	subsidy	
•	 lack	of	drug	interactions.
•	 	Give	initial	4	week	script;	arrange	for	return	for	
second	script	and	discussion	of	progress
•	 	Encourage	use	of	support	services
•	 	At	follow	up,	review	progress	and	problems:	
common	adverse	effects,	nausea	and	
abnormal	dreams
•	 	Check	for	neuropsychiatric	symptoms
•	 	Encourage	completion	of	12	weeks	of	therapy
•	 	If	quit,	further	12	weeks	available	on	PBS	to	
reduce	relapse
•	 	Consider	a	further	follow	up	visit	if	patient	
needs	extra	support.
Clinical suitability
Absence	of	contraindications	such	as	current	
or	past	seizures,	concurrent	monoamine	
oxidase	inhibitors,	pregnancy.	Caution	with	
other	conditions	or	drugs	that	lower	seizure	
threshold	(check	PI)
Patient choice
Reasons	to	prefer:
•	 PBS	subsidy
•	 oral	non-nicotine	preparation
•	 relapse	in	past	using	NRT
•	 	evidence	of	benefit	in	chronic	disease	and	
depression.
•	 	Give	initial	2	week	script;	arrange	for	return	
for	second	script	and	discussion	of	progress
•	 	Encourage	use	of	support	services
•	 	At	follow	up,	review	progress	and	adverse	
effects:	monitor	allergy	problems	(skin	rash)	
and	insomnia
•	 	Encourage	completion	of	at	least	7	weeks	of	
therapy
•	 	Consider	combination	treatment	if	
withdrawal	not	controlled
•	 	Consider	a	further	follow	up	visit	if	patient	
needs	extra	support.
Figure 2. Pharmacotherapy treatment algorithm for smoking cessation
Pharmacotherapy for smoking cessation
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First line pharmacotherapy options
First line options are medicines that have been shown to be effective and are licensed 
for smoking cessation. In Australia these are NRT (brands include Chemist’s Own 
Nicotine, Nicabate CQ®, Nicorette®, Nicotinell®, QuitX® and others), varenicline (brand 
name Champix®) and sustained release preparations of bupropion hydrochloride 
(brand names Buproprion-RL™, Clorprax®, Prexaton and Zyban SR®).
From current available evidence, varenicline is the most effective form of single 
pharmacotherapy for smoking cessation, but this is based on a limited number 
of comparison studies.91,95,96 However, there have been concerns raised about 
the neuropsychiatric adverse effects and the risk of cardiovascular events with 
varenicline. It has been shown that varenicline is more effective than bupropion in 
a number of studies. In the one prospective study comparing varenicline with NRT 
(21 mg/day), continuous abstinence was modestly higher with varenicline at the end 
of the treatment period (RR 1.29) but the difference was no longer significant by 6 
months.94,97 Further research is needed to determine whether varenicline is more 
effective than NRT, including the need for studies comparing varenicline to high dose 
NRT, combination NRT and other regimes such as pre-cessation NRT.
However, clinical assessment, context and patient preference are important in 
choosing the pharmacotherapy that is most likely to assist the smoker in an attempt 
to quit. Consideration should be given to factors such as the potential for adverse 
effects, possible drug interactions, previous experience with pharmacotherapy 
convenience and cost.98 Some smokers may prefer to use one or more forms of NRT, 
while others may prefer the non-nicotine options. An advantage of NRT is that it can be 
purchased without a prescription. One form of NRT (patch) is now subsidised by the 
Pharmaceutical Benefits Scheme (PBS) if provided in combination with counselling. 
Evidence
Pharmacotherapy with nicotine replacement therapy, varenicline or bupropion 
is an effective aid to assisting motivated smokers to quit. Level I
Recommendation
In the absence of contraindications, pharmacotherapy should be offered to 
all motivated smokers who have evidence of nicotine dependence. Choice of 
pharmacotherapy is based on clinical suitability and patient choice. Strength A
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Nicotine replacement therapy
Key points
• Using NRT to quit is always safer than continuing to smoke
• All forms of NRT (at equivalent doses) are similarly effective in aiding 
long term cessation 
• All forms of NRT can increase the rate of quitting by 50–70%
• Higher dose forms of NRT (4 mg) are more effective than lower dose 
forms (2 mg) for more addicted smokers
• More than one form of NRT can be used concurrently with increased 
success rates and no safety risks
• NRT can be given several weeks prior to smoking cessation to help 
smokers prepare for quitting
• NRT can be used by people with cardiovascular disease. Caution is 
advised for people in hospital for acute cardiovascular events, but 
if the alternative is active smoking, NRT can be used under medical 
supervision
• NRT can be used by smokers aged 12–17 years
• NRT may be appropriate in pregnant smokers if they have been 
unsuccessful in stopping smoking without NRT 
• Intermittent, short acting dosage forms (oral) are preferred in 
pregnancy to long acting dosage forms (patches).
Nicotine is the substance in tobacco that causes addiction – it makes people 
dependent on cigarettes, but it is the other chemicals in combusted tobacco that 
cause cancer, accelerate heart disease and affect other areas of health. The aim of 
NRT is to reduce withdrawal symptoms by providing some of the nicotine that would 
normally be obtained from cigarettes, without providing the harmful components of 
tobacco smoke. NRT is available over the counter in pharmacies, and some forms 
are available in supermarkets in Australia. Nicotine patches (15 mg and 21 mg) are 
subsidised on the PBS. None of the available forms of NRT (transdermal patch, gum, 
inhaler, lozenge and sublingual tablet) offer the same rapid nicotine delivery of a 
cigarette. 
Some oral forms of NRT are available in two strengths: 2 mg and 4 mg (gum 
and lozenge) and 1.5 mg and 4 mg (mini lozenge) (Table 4). The 4 mg version is 
recommended for more dependent smokers (20 or more cigarettes per day).93
Regular use of NRT beyond 12 months is not generally recommended. However, 
long term use of some forms of NRT has been reported and has not caused ill health 
effects – it may help some people remain abstinent97 and is safer than smoking.
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 Table 4. Nicotine replacement therapy initial dosing guidelines
Patient group Dose Duration 
(weeks)
Contraindications
(adapted from MIMS online 
2011)
Patch >10 cigarettes per day 
and weight >45 kg
21 mg/24 hr or 
15 mg/16 hr
>8 (Unscheduled) non-smokers; 
children under 12 years; 
hypersensitivity to nicotine or 
any component of the patch; 
diseases of the skin that may 
complicate patch therapy
<10 cigarettes per day or 
weight <45 kg or 
cardiovascular disease
14 mg/24 hr or 
10 mg/16 hr
>8 
Gum 10–20 cigarettes per day 2 mg 8–12  
per day
>8 (Unscheduled) non-tobacco 
users; known hypersensitivity 
to nicotine or any component 
of the gum; children (<12 
years)
>20 cigarettes per day 4 mg 6–10  
per day
>8 
Inhaler >10 cigarettes per day 6–12 cartridges 
per day
>8 (S2) Non-tobacco users; 
hypersensitivity to nicotine or 
menthol; children (<12 years)
Lozenge First cigarette 
>30 minutes after waking
1.5 mg or 2 mg 
1 lozenge every 
1–2 hr
>8 (Unscheduled) non-smokers; 
hypersensitivity to nicotine 
or any component of the 
lozenge; children (<12 years); 
phenylketonuria
First cigarette 
<30 minutes after waking
4 mg 1 lozenge 
every 1–2 hr
>8 
Sublingual
tablet
Low dependence 2 mg every 1–2 
hr
>8 (Unscheduled) non-tobacco 
users; known hypersensitivity 
to nicotine or any component 
of the tablet; children (<12 
years)
High dependence Two 2 mg every 
1–2 hr
>8 
Source: Adapted from Smoking cessation guidelines for Australian general practice. Canberra, 2004
Higher dose and combination NRT 
Combining two forms of NRT (patch plus oral form, such as lozenge or 
gum) has been shown to be more efficacious than a single form of nicotine 
replacement. The patch provides a steady background nicotine level and 
the oral forms provide relief for breakthrough cravings as needed. Health 
professionals should encourage smokers to use combined NRT if they are 
unable to quit using one NRT product alone, or experience cravings using only 
one form of NRT.93,99 In Australia, the combination of NRT patch and 2 mg gum, 
2 mg lozenge or 1.5 mg mini lozenge is licensed for smokers who have relapsed 
in the past or who experience cravings using only one form of NRT.100 Some 
experts now recommend combination therapy for all dependent smokers using 
NRT, rather than monotherapy. 
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Pre-cessation nicotine patch
There is evidence to support use of nicotine replacement prior to smoking 
cessation.  A meta-analysis found that the nicotine patch used prior to quit day 
increased success rates compared to standard therapy.101 The Therapeutic 
Goods Administration (TGA) approved approach involves using a 21 mg/24 hour 
patch (Nicabate® only brand currently approved) for 2 weeks before quitting, 
then continuing to use nicotine patch in the usual way for the quit attempt and 
adding oral NRT if needed. 
Reduce to quit
There is also evidence for use of NRT to help smokers who are not willing to 
quit abruptly to reduce their tobacco and then progress to quitting.102 The TGA 
approved approach (cut down then stop or reduce to quit) involves smokers 
using NRT to reduce the number of cigarettes they smoke before stopping 
completely within 6 months. However, a meta-analysis has found that reducing 
cigarettes smoked before quit day versus quitting abruptly, with no prior 
reduction, produced comparable quit rates.103 Health professionals should offer 
smokers the choice to quit in either of these ways. Further research is needed 
to investigate those categories of smokers who benefit the most from each 
method.
Safety
Using therapeutic nicotine is always safer than continuing to smoke. All forms of 
NRT can be used by patients with stable cardiovascular disease, but should be 
used with caution in people with recent myocardial infarction, unstable angina, 
severe arrhythmias and recent cerebrovascular events. 
NRT can be used by smokers who are pregnant, but alternative non-drug 
cessation strategies should be used first. Intermittent NRT dosage (oral forms) 
is preferred to deliver a lower daily dose of nicotine and to avoid continuous 
nicotine exposure. There is currently insufficient evidence to determine whether 
or not nicotine replacement therapy is effective or safe when used in pregnancy 
for smoking cessation.104 However, it is likely to be effective given the strength of 
data in non-pregnant smokers. Nicotine passes from the mother to child through 
breast milk, depending on the concentration of nicotine in the maternal blood, 
but the nicotine in breast milk is unlikely to be dangerous.105 Women who smoke 
should be encouraged to continue breastfeeding and provided with strategies to 
minimise the potential harm to their child associated with the secondhand smoke.
Because of the uncertainty of the safety of NRT used during pregnancy, 
pregnant women wishing to use NRT to quit should be supervised by a medical 
practitioner, or other suitably qualified professional.
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Side effects
Minor side effects are common with NRT use.100 Common adverse effects with 
NRT depend on the delivery system. For the patch, they include skin erythema, 
skin irritation and sleep disturbance (abnormal dreams). For gum, lozenge and 
sublingual tablet minor side effects include dyspepsia and nausea, and for the 
inhaler – mouth and throat irritation may occur.53 
Availability of nicotine patches on the PBS
Nicotine patches (15 mg over 16 hours and 21 mg over 24 hours) are listed on 
the PBS for use as an aid to quitting for people who participate in a support and 
counselling program. A maximum of one PBS subsidised 12 week course of 
nicotine patches (one original script plus two repeats) is subsidised per year. An 
authority prescription is required and the support program being used needs to 
be specified, eg. the GP’s practice, the Quitline or other suitable programs.
Lower strength patches and other nicotine products are not subsidised. The 
subsidised patches are not available at the same time as other PBS subsidised 
smoking cessation therapies (varenicline and bupropion), but if a person is 
unsuccessful quitting using the nicotine patches, then they are able to access 
PBS subsidised medicines during that same 12 month period. Only certain 
brands – one 15 mg/24 hour patch (Nicorette) and two 21 mg/24 hour patches 
(Nicotinell Step 1 and Nicabate P) – are listed.
Aboriginal and Torres Strait Islander people
People who identify as Aboriginal or Torres Strait Islander qualify for PBS 
authority listing that provides up to two courses per year of nicotine patches, 
each a maximum of 12 weeks. Under this listing, participation in a support and 
counselling program is recommended but not mandatory. Access to nicotine 
patches for Aboriginal and Torres Strait Islander people can be facilitated 
through the Closing the Gap PBS copayment measure (see page 43).
Health professionals should check for updated PBS listings at www.pbs.gov.au.
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Evidence
Nicotine transdermal patch, nicotine gum and nicotine inhaler all 
increase quit rates by 50–70% at 5–12 months compared with placebo, 
and regardless of the setting. Level I
There is no evidence of increased risk for use of NRT in people with 
stable cardiovascular disease. Level II
There is no evidence of an association between use of nicotine patch 
and acute cardiac events. Level II
There is currently a lack of evidence on the safety of NRT in pregnancy 
but international guidelines recommend use of NRT in certain 
circumstances. Level V
In more dependent smokers combinations of different forms of NRT 
(eg. patch plus gum) are more effective than one form alone. Level II
Recommendations
NRT should be recommended to nicotine dependent smokers. There 
is no significant difference in effectiveness of different forms of NRT 
in achieving cessation so choice of product depends on clinical and 
personal considerations. Strength A
NRT is safe to use in patients with stable cardiovascular disease. 
Strength A
NRT should be used with caution in patients who have had a recent 
myocardial infarction, unstable angina, severe arrhythmias or recent 
cerebrovascular events. Strength C
Use of NRT should be considered when a pregnant woman is 
otherwise unable to quit. Intermittent NRT is preferred to patches (lower 
total daily nicotine dose). Strength C
Combination NRT should be offered if patients are unable to remain 
abstinent or continue to experience withdrawal symptoms using one 
type of therapy. Strength A
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Varenicline
Key points
• Varenicline is a nicotine partial agonist drug for smoking cessation
• It can more than double the chances of long term quitting
• It has been found to be more effective than bupropion, but there is a 
lack of studies directly comparing it to NRT
• Smokers using varenicline should be advised to report unusual 
mood changes, depression, behaviour disturbance and suicidal 
thoughts and if these occur to stop using the medicine 
• The risk of cardiovascular events should be discussed with smokers 
and weighed up against the known benefits of the drug on smoking 
cessation
• There is no evidence of the efficacy of combining varenicline with any 
other smoking cessation pharmacotherapy
• The target quit day is in the second week of treatment, but patients 
should continue to use varenicline as the rate of successful 
cessation rises during the standard 12 week treatment period
• Longer term use (a second 12 week course) slightly reduces relapse 
for up to one year in people who have successfully quit at the end of 
week 12. 
Varenicline is a nicotinic acetylcholine-receptor partial agonist. It was developed 
specifically for smoking cessation by targeting the nicotinic acetylcholine (ACh) 
receptor in the reward centres in the brain. Varenicline binds with high affinity 
at the α4β2 nicotinic ACh receptor, where it acts as a partial agonist to alleviate 
symptoms of craving and withdrawal. At the same time, if a cigarette is smoked, 
the drug prevents inhaled nicotine from activating the α4β2 receptor sufficiently 
to cause the pleasure and reward response. This mechanism may explain why 
quitting can occur later in a course of treatment with varenicline.
Efficacy
Varenicline at standard dose can increase the chances of successful 
long term smoking cessation between two and threefold compared with 
pharmacologically unassisted quit attempts.91,95 In two randomised, double 
blind clinical trials with identical study designs, varenicline was compared to 
both bupropion and to placebo.106,107 All three groups received brief behavioural 
counselling. When the results of these studies were combined in a meta-
analysis, the abstinence rate for varenicline was significantly better at 1 year 
than bupropion (odds ratio [OR] 1.58; 95% confidence interval [CI]: 1.22–2.05), 
and placebo (OR 2.96; 95% CI: 2.12–4.12, p≤0.0001).95
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Two open label randomised trials have compared varenicline with nicotine 
patch,94,108 although the more recent study was too small to contribute usefully 
to a pooled estimate in the Cochrane review.91,109 At 52 weeks, the earlier study 
reported a larger benefit for varenicline over nicotine patch that almost reached 
statistical significance (RR 1.29; 95% CI: 0.99–1.67) for biochemically confirmed 
continuous abstinence.94 In the trials, varenicline was shown to significantly 
reduce craving and other withdrawal symptoms.
Prolonged use of varenicline has also been shown to reduce relapse. In subjects 
who stopped smoking at the end of 12 weeks of treatment, an additional 12 
weeks of treatment was more beneficial than placebo in maintaining abstinence 
to the end of treatment and to 1 year from the start of treatment. However, the 
difference in continuous abstinence for weeks 13–52 between intervention and 
control groups was small.110 The benefit appears to be maintained only for the 
period of use of varenicline. 
Safety
The effectiveness and safety of varenicline has not been studied in patients 
with psychiatric conditions. Postmarketing, there have been reports of mood 
changes, depression, behaviour disturbance and suicidal ideation possibly 
associated with varenicline. Accordingly, prescribers have been advised to 
monitor patients for emergence of these problems.94 However, a meta-analysis 
has found that such reports are so far not substantiated as being due to the 
drug.91 Another study of drug adverse events reports in the USA found an 
increased risk of depression and suicidal behaviours related to varenicline 
compared to NRT,111 However, submission of adverse events reports can be 
influenced by publicity and does not necessarily prove causality. It is important 
that prescribers ask patients to report any mood or behaviour changes. 
Smokers should be advised to stop taking varenicline at the first sign of any 
of these symptoms. Although a causal relationship of these symptoms with 
varenicline has not been demonstrated, prescribers should weigh up possible 
risks of varenicline against the benefits of smoking cessation. 
A meta-analysis of 14 placebo controlled trials in a total of 8216 people, with 
and without cardiovascular disease, reported an association between use of 
varenicline and an increased risk of cardiovascular events (non-fatal myocardial 
infarction, need for coronary revascularisation and new diagnosis of peripheral 
vascular disease or admission for a procedure to treat peripheral vascular 
disease), OR 1.72; 95% CI: 1.09–2.71.112 From the meta-analysis, based on one 
study in patients with cardiovascular disease and data reported in the others, it 
is possible that use of varenicline is associated with an increase risk in selected 
non-fatal cardiovascular events. The US Food and Drug Administration (FDA) 
guidance in relation to this finding is that the absolute risk with varenicline, in 
relation to its efficacy, is small but that health professionals should discuss the 
risk of cardiovascular events with their clients and carefully balance the risks 
associated with varenicline use against the known benefits of the drug on 
smoking cessation. In Australia, the TGA has not, to date, added a caution for 
use of varenicline in patients with cardiovascular disease.
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Side effects
Nausea is the most common adverse effect of varenicline and was reported 
in studies of almost 30% of smokers, although less than 3% discontinued 
treatment due to nausea. Abnormal dreams were also more common in the 
varenicline group (13.1%) than either the bupropion (5.9%) or placebo groups 
(3.5%). No clinically meaningful drug interactions have been identified.
Varenicline is excreted almost entirely by the kidneys. For people with creatinine 
clearance < 30 mL/min, the recommended daily dosage is 1 mg/day  
(0.5 mg/day for 3 days then increasing to 1 mg/day). Avoid varenicline in end 
stage renal failure in favour of other approaches to smoking cessation. Dose 
adjustment is not routinely required in elderly people or in people with hepatic 
impairment.113
Availability of varenicline on the PBS 
Varenicline is available in Australia on the PBS as short term adjunctive therapy 
for nicotine dependence. It can be prescribed for up to 24 weeks of continuous 
therapy for smoking cessation for smokers who are enrolled in a support and 
counselling program and who are abstinent at 12 weeks. 
The first script is a starter pack lasting 4 weeks (including dose titration), 
followed by a maintenance batch for 8 weeks of treatment. 
A third authority prescription is required for a final 12 weeks of treatment, for 
those who respond to the first 12 weeks (Table 5). The medicine can be taken 
whole with water and food to help reduce nausea.
Health professionals should check for updated PBS listings at www.pbs.gov.au.
Table 5. Varenicline dosing guidelines
A course of varenicline requires two or three authority prescriptions.
• An initial 4 weeks of treatment (including dose titration)
  Smokers should start varenicline and then set a quit date 1–2 weeks after 
starting. The exact date can be determined on the basis of perceived 
effects of the drug, but should not exceed 2 weeks. The recommended 
dose of varenicline is 1 mg twice per day following a 1 week titration as 
follows:
 Days 1–3  0.5 mg once per day
 Days 4–7  0.5 mg twice per day
 Day 8 on  1 mg twice per day until the end of the 4 week course
•  A further 8 weeks of treatment: continue with 1 mg twice per day until the 
end of the 8 week course
•  A final 12 weeks of treatment for those who successfully quit at 12 weeks: 
continue with 1 mg twice per day until the end of the 12 week course.
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Evidence
Varenicline is an efficacious smoking cessation treatment. Level I
Recommendation
Varenicline should be recommended to smokers who have been assessed as 
clinically suitable for this medication and should be provided in combination 
with counselling. Strength A
Bupropion
Key points
• Bupropion is a non-nicotine oral therapy, originally developed as an 
antidepressant
• It significantly increases cessation rate compared with placebo
• It has been shown to be effective for smokers with depression, 
cardiac disease and respiratory diseases, including COPD
• It has been shown to improve short term abstinence rates for people 
with schizophrenia
• Bupropion has been shown to be not as effective as varenicline for 
smoking cessation
• There is limited evidence of the safety or efficacy of combining 
bupropion with NRT and no evidence on its combination with 
varenicline.
Originally developed as an antidepressant, bupropion is a non-nicotine oral therapy 
that reduces the urge to smoke and reduces symptoms from nicotine withdrawal. 
Efficacy
Bupropion significantly increases the long term cessation rate compared 
with placebo RR 1.69; 95% CI: 1.53–1.85)92 over 12 months. Data from two 
randomised controlled trials showed 9% and 19% of smokers had not smoked 
for the 12 months following placebo and bupropion therapy, respectively.99,114 
It has been shown to be effective in a range of patient populations including 
smokers with depression, cardiac disease and respiratory diseases including 
COPD.115 It has also been shown to improve short term abstinence rates for 
people with schizophrenia.116
Clinical trials have shown that bupropion is not as effective as varenicline. 
However, bupropion is a useful option in cases where varenicline is not 
appropriate (patient choice, or as a result of side effects). There is also more 
evidence for the use of bupropion than varenicline in smokers with depression 
or schizophrenia. There is insufficient evidence that adding bupropion to NRT 
provides an additional long term benefit.92
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Safety
Bupropion is contraindicated in patients with a history of seizures, eating disorders 
and those taking monoamine oxidase inhibitors. The current recommendation is 
that it should be used with caution in people taking medications that can lower 
seizure threshold, such as antidepressants and oral hypoglycaemic agents.91 
Alternative medication should be considered in these situations. 
Side effects
Seizures are the most clinically important adverse effect (0.1% risk) and fatalities 
have been reported. Common adverse effects are insomnia, headache, dry 
mouth, nausea, dizziness and anxiety.115 Bupropion can be used in combination 
with NRT, but blood pressure should be monitored.115
Availability of sustained release bupropion on the PBS
Since 2001, sustained release bupropion has been available in Australia as 
a PBS authority item once per year. It is a short term adjunctive therapy for 
nicotine dependence in conjunction with counselling with the goal of maintaining 
abstinence.
Bupropion is available as a starter pack of 30 tablets and a continuation pack 
of 90 tablets. The dose of bupropion is 150 mg once per day for the first 3 days 
and then increased to 150 mg twice per day. The patient should stop smoking 
in the second week of treatment. 
Health professionals should check for updated PBS listings at www.pbs.gov.au.
Evidence
Bupropion sustained release is an efficacious smoking cessation treatment. 
Level I
Combination treatment with bupropion and nicotine replacement therapy is 
effective. Level II
Recommendations
Bupropion sustained release should be recommended to smokers who 
have been assessed as clinically suitable for this medication and provided in 
combination with counselling. Strength A
Combination treatment with bupropion and nicotine patch can be considered 
where a smoker has not been successful on an adequate trial of one of these 
therapies. Blood pressure should be monitored during treatment. Strength C
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Nortriptyline
The tricyclic antidepressant, nortriptyline, has been shown to approximately 
double cessation rates compared to placebo (OR: 2.3).92,117 A systematic review 
shows that the use of nortriptyline for smoking cessation resulted in higher 
prolonged abstinence rates after at least 6 months, compared to placebo 
treatment.118 The efficacy of nortriptyline does not appear to be affected by 
a past history of depression, but it is limited in its application by its potential 
for side effects including dry mouth, constipation, nausea, sedation and 
headaches, and a risk of arrhythmia in patients with cardiovascular disease. 
Nortriptyline can be dangerous in overdose.
Nortriptyline is not registered for smoking cessation in Australia. 
The dose of nortriptyline used for smoking cessation is approximately 75 mg/day 
for 12 weeks. Further information about dose titration can be obtained from New 
Zealand Smoking Cessation Guidelines.13
Evidence
Nortriptyline is an efficacious smoking cessation treatment in people with and 
without a history of depression. Level II
Recommendation
Nortriptyline should only be considered as a second line agent due to its 
adverse effects profile. Strength B
Future options
A number of novel tobacco cessation therapies are in development.119,120 
Cytisine, a naturally occurring substance chemically related to varenicline, has 
been used for smoking cessation for decades in parts of Eastern Europe, but 
robust evidence of its effectiveness is lacking and there is limited evidence of 
its role in smoking cessation relative to other options.91 A trial investigating this 
question is currently underway in New Zealand – a recent study has shown 
that cytisine is more effective than placebo for smoking cessation.121
Also in development are antinicotine vaccines. The rationale for immunisation 
against nicotine is to induce antibodies that bind nicotine in the blood, thereby 
preventing it from crossing the blood brain barrier. It is postulated that with 
less nicotine reaching the brain immediately after smoking, the vicious cycle 
between smoking and nicotine related gratification will be broken. Phase II 
studies have evaluated three different vaccines, NicVAX®, Nicotine-Qbeta™ 
and TA-NIC. While some results from these small studies are promising, the 
NicVAX data are disappointing. The vaccines need to be administered regularly 
to maintain effects – they will not provide long term protection with a single 
course of treatment. Larger ongoing studies of a longer acting vaccine are 
needed before this approach can be evaluated.122,123
Other pharmacotherapy options
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Given that the current available first line medications are all efficacious, and 
non-drug factors make a substantial contribution to the likelihood of quitting 
successfully,100 choice should be based on clinical suitability and patient 
preference (see Figure 2. Pharmacotherapy treatment algorithm for tobacco 
smoking cessation).
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Although many smokers are likely to attempt quitting unassisted, this 
approach has a low likelihood of succeeding (3–6% success rate) on any given 
attempt.10,124,125 The most successful quit approach for those who are nicotine 
dependent is counselling and support combined with first line pharmacotherapy 
and follow up.10,122,126 Health professionals should offer to assist their patients/
clients with a quit attempt, using pharmacotherapy and counselling, either within 
the health service or by referring them for intensive support to a telephone 
Quitline (13 7848),50 or to a tobacco treatment specialist.
Health professionals should be aware of extravagant claims of success for 
interventions that have not been subjected to rigorous testing and for which 
there is no clinical evidence to support. 
The following smoking cessation interventions have been proven to be effective.
Brief motivational advice from health professionals
There is strong evidence that advice from health professionals (doctors, 
nurses, nurse practitioners, medical assistants, dentists, hygienists, respiratory 
therapists, mental health counsellors, pharmacists) is effective in encouraging 
smoking cessation.26–30,41 Health professionals can make a difference with even 
a minimal (less than 3 minutes) intervention RR 1.66; 95% CI: 1.42–1.94).26 More 
intense interventions can result in better outcomes, but may not be practical in 
many clinical contexts.10 (See page 7, The role of health professionals.)
Every smoker should be offered at least a brief intervention for smoking 
cessation, which should include one or more of the following:127 
• simple opportunistic advice to consider quitting
• an assessment of the smoker’s commitment to quit 
• offer of pharmacotherapy and/or behavioural support 
• self help material 
• referral to more intensive, proactive support such as Quitline (13 7848), a 
tobacco treatment specialist or cessation programs. 
Evidence
Brief smoking cessation advice from health professionals delivered 
opportunistically during routine consultations has a modest effect size,  
but substantial potential public health benefit. Level I
Recommendation
Offer brief cessation advice in routine consultations whenever possible (at least 
annually). Strength A
Other forms of treatment and support for 
smoking cessation
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Group or individual counselling
There is clear evidence that both individual (RR 1.39; 95% CI: 1.24–1.57)128 and 
group counselling (RR 1.98; 95% CI: 1.60–2.46)129 increases quit rates over that 
of minimal support.  
Individual counselling typically involves weekly face-to-face meetings between a 
smoker and a counsellor trained in smoking cessation over a period of at least 
4 weeks after the quit date and is normally combined with pharmacotherapy. 
Group behaviour therapy involves scheduled meetings (typically 4–8) where 
smokers receive information, advice and encouragement and some form of 
behavioural intervention.127 
Counselling should include practical advice consisting of problem solving and 
skills training, and social support as part of the treatment. Group techniques, 
which focus on skills training and provide mutual support, can also be effective 
for those who find this method appropriate.53 
In some states, quitlines keep registers of local support programs led by 
approved providers.
Telephone counselling and quitlines
Telephone counselling provides advice, encouragement and support by 
specialist counsellors to smokers who want to quit, or who have recently quit. 
Counsellors can call the client (a proactive service) usually several times over 
the period leading up to, and the month following, their quit attempt or the 
client can call the service (a reactive service). There is stronger evidence that 
the proactive form of support is more effective,130–133 in part because most 
smokers do not make the call to Quitline often enough to get the full benefit, 
yet they readily accept and appreciate proactive calls. Telephone counselling, 
also known as Quitline, is provided through state or national services available 
in many countries (eg. Australia, New Zealand, United Kingdom, United States). 
A review in New Zealand of the cost effectiveness of a variety of interventions 
found quitlines, particularly when they include the use of pharmacotherapy, to 
be among the highest rated.34
Adding Quitline counselling to pharmacotherapy and minimal intervention 
increases abstinence rates (RR 1.29; 95% CI: 1.20–1.38).130
Evidence
Telephone callback counselling services are effective in assisting cessation for 
smokers who are ready to quit. Level II 
Recommendation
Referral to such services should be considered for this group of smokers. 
Strength A
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Quitline services in Australia
Quitline (13 7848) (13 QUIT) exists in all Australian states and territories. Quitline 
can provide a free Quit pack and telephone counselling assistance. Quitline can 
also assist in linking callers into community programs. Counsellors can help callers 
find a course and email the link to them. 
Calls are charged at the cost of a local call (about 25 cents, mobile telephone 
extra) from both rural and metropolitan areas. 
All Quitline services in Australia have agreed to national minimum standards of 
service delivery.
• In most states and territories, smokers are offered free proactive telephone 
counselling. Proactive or callback counselling protocols usually allow up to two 
sessions pre-quit and four post-quit over the first month, with two in the first 
week, but vary from state to state 
• Fax referral to Quitline (smokers can be referred by all health professionals to 
the Quitline for extended support using the fax referral sheet). Services provide 
feedback to health professionals regarding patients referred to a Quitline (see 
Appendix 2 for fax referral form) 
• Processes for online referral to Quitline through patient management software 
are likely to become available
• Quitline adviser, course leader or coach
• Adolescent protocols
• Indigenous counsellors or indigenous liaison people are available at Quitline 
Australia wide
• Self help books (eg. www.quitbecauseyoucan.org.au).
Services for those from culturally and linguistically diverse backgrounds:
• In some states, bilingual educators conduct information sessions in a number 
of community languages. Visit www.quit.org.au. 
• Community language specific Quitline telephone numbers available (see below)
Web-based material:
• iCanQuit: www.iCanQuit.com.au
• Quit Coach: www.quitcoach.org.au.
Self help materials
Self help interventions for smoking cessation in the form of structured 
programs in written (books, brochures, manuals) or electronic (CDs, online) 
formats provide support and advice for smokers without the help of health 
professionals, counsellors or group support. On their own, these materials show 
only marginal effect compared to no intervention, and there is no evidence that 
they have an additional benefit when used with other interventions, such as 
advice from a health professional or NRT.131 There is evidence that materials 
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tailored for individual smokers in different tobacco dependent populations are 
more effective than untailored materials.10,133
Two studies have found that text message mobile phone support programs 
are effective in the short term (6 weeks)134 and long term.135 Combined internet/
mobile telephone programs can be effective for up to 12 months for assisting 
smokers to quit.136,137
Online smoking cessation interventions are low cost and have the potential to 
reach a large number of smokers.138,139 A major advantage of the internet over 
printed material is its interactivity and the ability to tailor information to individual 
needs, but relatively few sites make use of this possibility (for a good example of 
a site designed to tailor information to individual needs, see the Quit Coach at 
www.quitcoach.org.au).16 Web based programs are a promising delivery system 
for assisting smokers to quit, but further research is needed to identify their 
most effective use.
Ineffective and unproven approaches to smoking cessation
There are several quitting methods, which are in widespread use, but have not yet 
been shown in well designed trials to be effective for quitting other than a placebo 
effect – or more than counselling and support provided at the same time.16
There are some approaches that have the potential to assist with maintaining 
long term smoking cessation, but they have not yet been adequately 
investigated for cessation. These approaches include physical activity, the 
Alan Carr method and electronic nicotine delivery systems (ENDS), also called 
electronic cigarettes or e-cigarettes.
Hypnotherapy (without counselling)
Hypnotherapy is widely promoted as an effective way to stop smoking. It is said 
to assist smoking cessation by weakening the desire to smoke, or strengthening 
the will to stop. Despite being in use for some decades, there are only a few 
well designed studies to evaluate its use.16 A Cochrane meta-analysis has 
concluded that, although it is possible that hypnotherapy could be as effective 
as counselling treatment on quit rates, there is not enough high quality evidence 
at this time to be certain.140
Acupuncture
People sometimes have acupuncture for quitting smoking with the aim of 
reducing withdrawal symptoms. Related therapies include acupressure, laser 
therapy and electrical stimulation. At present, there is no consistent evidence that 
acupuncture, or any related therapy, is better than doing nothing. Well designed 
trials of acupuncture, acupressure and laser stimulation are needed before these 
treatments can be recommended as effective in smoking cessation.141
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Evidence
There is no significant effect of acupuncture or hypnotherapy in smoking 
cessation. Level I
Recommendation
On the evidence available acupuncture and hypnotherapy are not 
recommended as aids to smoking cessation. Strength A
Naltrexone
At present there is inconclusive evidence that the long acting, opioid antagonist 
naltrexone can increase the likelihood of smoking cessation. It is promoted to 
help reduce nicotine addiction by blocking some of the rewarding effects of 
smoking.142 Data from larger trials are needed to confirm naltrexone’s efficacy for 
smoking cessation.
Aversive or rapid smoking
There is limited evidence to suggest that rapid (or aversive) smoking may 
be effective.143 However, this technique should not be attempted without 
appropriate training.
Biomedical feedback
Demonstration of the effects of smoking, with the exception of spirometry,144 
has not been shown to increase quit rates. Strategies used include carbon 
monoxide results, vascular ultrasounds and genetic susceptibility.145
Physical activity
There are two major aspects to quitting tobacco use: overcoming nicotine 
addiction and changing lifestyle. It is well known that increased physical activity 
has many benefits for a healthy life. Exercise has been investigated as a way 
of helping with symptoms of nicotine withdrawal and cravings during attempts 
to quit. Exercise may also help by increasing self esteem and might help to 
manage the weight gain that often follows quitting. However, there is currently 
no evidence to show higher abstinence rates long term with exercise alone.146
Well designed studies with larger sample sizes and sufficiently intense 
interventions are underway to test whether physical activity could be 
recommended as an adjunct to cessation.147,148 However, increased activity 
should not be discouraged as part of a support program as it brings other 
health advantages.
Allen Carr method
Although it has considerable popular support, there is no high quality, empirical 
evidence that the Allen Carr method is effective.13 
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St John’s wort
The herbal antidepressant St John’s wort (Hypericum perforatum) herb extract 
has not been shown to aid in smoking cessation. There is as yet no convincing 
evidence that St John’s wort, alone or with individual motivational and 
behavioural support, is likely to be effective as an aid in smoking cessation.149
Other nicotine related agents 
NicoBloc® and Nicobrevin are nicotine related agents, which are occasionally 
recommended by some healthcare professionals. These are available in some 
pharmacies,150 despite a lack of any empirical evidence of effectiveness.13,151
While available in many countries, electronic cigarettes (e-cigarettes), which 
deliver nicotine by inhalation, are not regulated. Before these products can be 
recommended for consumers, research must be conducted on the safety and 
efficacy for smoking cessation.152
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Some smokers are unable or unwilling to completely quit smoking. It has been 
proposed that reducing the number of cigarettes smoked per day has long 
term benefits. However, it is not clear whether this strategy decreases the risk 
for tobacco related diseases. Research has shown that smoking reduction by 
50% significantly reduces the risk of lung cancer in heavy smokers (15 or more 
cigarettes each day).153 But studies have not shown a decrease of risk of fatal or 
non-fatal myocardial infarction, hospitalisation for COPD or all cause mortality 
compared with heavy smokers who do not change smoking habits.154–156 Health 
professionals should always encourage smoking cessation as the proven 
method of reducing harm from smoking.
There is insufficient evidence about long term benefit to support the use of 
interventions intended to help smokers reduce, but not quit smoking. Some 
people who do not wish to quit can be helped to cut down the number of 
cigarettes smoked by using nicotine gum or nicotine inhaler. Because the long 
term health benefit of a reduction in smoking rate is unclear, this use of NRT 
is more appropriate before quitting.157 Smokers who use NRT for smoking 
reduction are approximately twice as likely to progress to quitting than those 
who do not.157 
Smoking reduction rather than 
smoking cessation
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Relapse 
Relapse is common. Most smokers make repeated quit attempts before finally 
achieving long term abstinence. Relapse is associated with the severity of 
withdrawal symptoms and the association of factors, such as stress and weight 
gain, with the process of quitting tobacco. There is no intervention that is proven 
to prevent relapse,158 but advice and pharmacotherapy are recommended to 
treat symptoms of withdrawal, stress and weight gain.159
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Although the proportion of people aged 14 years of age and over smoking 
tobacco daily has continued to decline from 16.6% in 2007, to 15.1% in 2010,1 
the smoking rate is lower in more affluent, better educated segments of the 
community while the number of smokers in disadvantaged groups remains 
disproportionately high. The proportion of Australians who smoke is inversely 
related to the socioeconomic status of where they live – in 2010, 24.6% of 
people in areas with the lowest socioeconomic status smoked compared with 
12.5% in areas with the highest socioeconomic status.1
In many countries, including Australia, social inequalities in tobacco use 
contribute to inequalities in health.51 There is a clear relationship between 
smoking and socioeconomic status, with disadvantaged groups in the 
population being more likely to start smoking and to remain long term smokers. 
In particular, three sociodemographic variables are closely connected with 
the likelihood of smoking: education, family income and Index of Relative 
Socioeconomic Disadvantage.18,160 The most recent National Health Survey 
2004–2005 indicates that smokers tend to report other lifestyle risk factors 
such as higher levels of alcohol consumption, lower daily fruit and vegetable 
intake and lower levels of exercise.24 There is extensive evidence that tobacco 
use contributes to poverty and inequality, encouraging smokers to quit has the 
potential to improve health and also to alleviate poverty.
The same guidelines for quitting smoking apply to all groups – every opportunity 
should be taken to offer all smokers advice and support to stop smoking.7 
Counselling and behavioural interventions may be modified to be appropriate for 
the individual smoker. Quitlines and other service providers have been trained 
for clients from many high prevalence groups, including Aboriginal and Torres 
Strait Islander people. All smokers should be offered pharmacotherapy, unless 
contraindicated.
Aboriginal and Torres Strait Islander people
Half of the Aboriginal and Torres Strait Islander population are current daily 
smokers, a prevalence rate more than double that of the non-indigenous 
Australian population.1,2 Since the 1994 National Health Survey, smoking rates 
have decreased for the total Australian population, but they have remained 
stable over this period for the indigenous population, falling slightly for the 
first time over the period 2002–2008.2 If the smoking rate among Indigenous 
Australians can be reduced to that of the non-indigenous population, the 
overall indigenous burden of disease should fall by around 6.5%, and provide 
improved life outcomes for around 420 Aboriginal and Torres Strait Islander 
people each year.161 
Compared with other Australians, Aboriginal and Torres Strait Islander 
people experience socioeconomic disadvantage across a range of indicators 
including education, employment, income and housing. Because of the strong 
association between low socioeconomic status, poor health and increased 
exposure to health risk factors, smoking is a major contributor to the 17 year 
life expectancy gap between Indigenous and non-Indigenous Australians. 
Smoking cessation in high prevalence 
populations
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Aboriginal and Torres Strait Islander people experience higher mortality from 
a number of smoking related diseases (including cardiovascular diseases, a 
number of cancers and respiratory disease) compared to the general Australian 
population.162 
Though various smoking cessation methods have been shown to be effective 
across different racial and ethnic groups in other countries,99 there has been 
a lack of research and evaluation of tobacco interventions in the Indigenous 
Australian population. Smoking cessation methods identified as being effective, 
such as brief advice and pharmacotherapy, should be provided for all smokers. 
Effective smoking cessation methods should be modified or tailored to meet 
the needs of Aboriginal and Torres Strait Islander people. This approach can 
involve working in collaboration with Aboriginal Health Workers. Appropriate 
cessation services for Aboriginal and Torres Strait Islander people can be 
found at the Centre for Excellence in Indigenous Tobacco Control (CEITC) at 
www.ceitc.org.au/quitting_resources. Specific barriers to smoking cessation 
treatment for Aboriginal and Torres Strait Islander people, such as the social 
context that normalises smoking, are being addressed by healthcare workers in 
many Aboriginal communities. There is also evidence of less knowledge about 
the harmful effects of tobacco smoking among Aboriginal and Torres Strait 
Islander people, as well as evidence that this population uses medicines at a 
lower rate than other Australians – despite initiatives in place to improve access 
to treatment. Other factors such as a lack of availability and access to culturally 
appropriate health services, language barriers and high rates of smoking among 
Aboriginal health workers are a significant barrier to the success of smoking 
cessation strategies for indigenous communities.163
People who identify as Aboriginal or Torres Strait Islander qualify for the PBS 
Authority listing for NRT, which provides up to two courses per year of nicotine 
patches, each of a maximum of 12 weeks. Under this listing, participation in a 
support and counselling program is recommended but not mandatory.
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Closing the Gap PBS copayment measure 
The Closing the Gap (CTG) measure is part of the Australian Government’s 
Indigenous Chronic Disease Package, established to improve access to 
medicines by reducing the cost of accessing PBS medicines for eligible 
Aboriginal and Torres Strait Islander people who are living with or are at risk of 
chronic disease.
Under this measure, eligible patients must be registered at a rural or urban 
indigenous health service, or a general practice that participates in the 
Indigenous Health Incentive (IHI) under the Practice Incentives Program (PIP) in 
order to receive a CTG annotated PBS prescription.
Depending on the indigenous patient’s concessional status, when a CTG 
annotated prescription is dispensed at a pharmacy, the patient pays a 
lower, or nil, copayment for all PBS medicines. A concessional patient’s co-
payment reduces to nil and a general patient’s copayment reduces to that of 
a concessional patient. Some suppliers of PBS medicines impose a brand 
premium on some brands of medicine, which the patient must pay. Brands 
that carry a manufacturer’s surcharge are indicated by a ‘B’ on the PBS 
Schedule.
For further information email PBS-Indigenous@health.gov.au or visit  
www.health.gov.au/tackling-chronic-disease.
Culturally and linguistically diverse groups
Prevalence of tobacco use in culturally and linguistically diverse groups in 
Australia varies from one community to another. Smoking is more common in 
men from Vietnamese and Chinese backgrounds and men and women from 
Middle Eastern backgrounds. People born in Oceania (New Zealand, Melanesia, 
Micronesia and Polynesia), Southern and Eastern Europe, and North West 
Europe were the most likely to report high rates of current smoking (24%, 23% 
and 22% respectively).24 However, average smoking rates in some of these 
communities are lower than for the rest of the Australian population.24 Tobacco 
is more commonly used via waterpipes in the Middle Eastern and African 
communities and by chewing it in the Burmese community rather than smoking 
cigarettes.
Some smokers in culturally and linguistically diverse groups in Australia 
face extra barriers to quitting, including a lack of awareness of the health 
consequences of smoking and secondhand smoke, lack of tobacco control 
regulations and norms in their culture of origin and difficulties accessing health 
information because of low literacy in English.16 These problems are most 
common among recently arrived groups and refugees.
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Health professionals should offer advice, support and pharmacotherapy for 
all smokers. Support for cessation for these groups should use culturally 
appropriate resource materials. 
The telephone Quitline service provides printed resources in 13 languages other 
than English, and callers can ask to have their call returned with an interpreter, in 
a range of languages other than English. Bilingual educators from Quit Victoria 
conduct information sessions in a number of community languages (www.quit.
org.au) and the NSW Multicultural Health Communication Service provides 
information and services to help health professionals communicate with non-
English speaking communities (www.mhcs.health.nsw.gov.au).
Community language Quitline telephone numbers
Arabic  1300 7848 03
Chinese (Cantonese and Mandarin)  1300 7848 36
Italian  1300 7848 61 
Vietnamese  1300 7848 65 
Korean  1300 7848 23 
Greek  1300 7848 59
Spanish  1300 7848 25
45Healthy Profession. Healthy Australia.
The RACGP 
Supporting smoking cessation: a guide for health professionals
There are several population groups for whom there are particular implications 
regarding nicotine dependence and the effects of smoking, as well as the 
use of medicines for smoking cessation. Many of these groups (children and 
adolescents, pregnant and lactating women, people with mental illnesses, 
people with substance use disorders and people with smoking related diseases) 
have not been studied in clinical trials of pharmacotherapy for smoking 
cessation. However, the same guidelines for quitting smoking apply to all 
groups – every opportunity should be taken to offer all smokers advice and 
support to stop smoking. Counselling and behavioural interventions may be 
modified to be appropriate for the individual smoker.6 In addition, all smokers 
should be offered pharmacotherapy and referred for intensive treatment to the 
telephone Quitline (13 7848), other cessation programs or local face-to-face 
services where available.  
Aboriginal and Torres Strait Island people are particularly vulnerable to tobacco 
use and consequent disease caused by tobacco use. This group is highly 
represented in many categories of those with special needs: pregnant women, 
adolescents, prisoners, people with substance use problems and people with 
smoking related diseases such as diabetes.
Pregnant and lactating women 
As well as the serious long term health consequences for the mother, cigarette 
smoking by pregnant women causes a range of adverse fetal outcomes 
including stillbirth, spontaneous abortion, reduced fetal growth, premature birth, 
low birth weight (a key indicator of infant health), placental abruption, sudden 
infant death, cleft palate, cleft lip and childhood cancers.10 Approximately 17% 
of women in Australia smoke during pregnancy164 and 20% of women who are 
pregnant or breastfeeding continue to smoke.165 
Pregnant women who are most disadvantaged are more than four times more 
likely to smoke than women who are least disadvantaged (28% compared to 
6%) and Aboriginal or Torres Strait Islander women are more than three times 
more likely to smoke during pregnancy than non-indigenous women (53% 
compared with 16%).16
Although 20–30% of women quit when they become pregnant, about 70% of 
these women relapse either during pregnancy, or after the baby is born. This is 
an important group of smokers to identify as they have made a quit attempt and 
are motivated. Smoking cessation interventions have been shown to be effective 
during pregnancy – overall by approximately 6%.166 Relapse in the postpartum 
period is high although there is evidence that this rate could be reduced by 
smoking cessation interventions at this time, but the difference is not significant 
at longer follow up.166 Health professionals should inform pregnant women and 
new mothers of the dangers of passive smoking to newborn babies and young 
children.
Smoking cessation in populations with 
special needs
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The only safe level of smoking in pregnancy is not smoking at all because: 
• any level of nicotine or tobacco smoke exposure increases the risk of adverse 
effects23,167–169
• the greatest gain in health benefits comes from quitting rather than cutting 
down.14,23,170
While not smoking at all in pregnancy has the greatest benefits to both the fetus 
and mother, quitting at any point throughout pregnancy has benefits. Therefore, 
health professionals should offer cessation interventions to pregnant smokers 
as soon as possible in the pregnancy, throughout the pregnancy, and beyond. 
Because of the uncertainty of the safety of NRT used during pregnancy, 
pregnant women wishing to use NRT to quit should be supervised by a medical 
practitioner, or other suitably qualified heath professional.
Many pregnant women do not disclose their smoking status to a health 
professional – some guidelines recommend multiple choice question formats to 
improve disclosure. Health professionals should encourage pregnant smokers 
to attempt cessation using counselling, advice and support interventions 
before using pharmacological approaches as the efficacy and safety of these 
approaches during pregnancy are not well documented.23 Pharmacotherapy 
should be considered for pregnant women only if the increased likelihood of 
quitting outweighs the harmful effects on the fetus of nicotine replacement 
therapy and possible continued smoking.23 Pregnant women should be 
encouraged to use Quitline. If these quit attempts are unsuccessful, and the 
woman is motivated to quit, NRT could be considered. 
There is limited evidence of the effectiveness of NRT in helping pregnant women 
stop smoking.166 The main benefits of using NRT are the removal of the other 
toxins contained in tobacco smoke and the lower dose of nicotine delivered by 
NRT than tobacco smoke.13 NRT can be used by pregnant and breastfeeding 
mothers, but the risks and benefits should be explained carefully to the woman 
and the clinician supervising the pregnancy should be consulted.6,16
In general, intermittent (oral) NRT should be used during pregnancy to deliver a 
lower total daily nicotine dose.13 If patches are used by pregnant women, they 
should be removed before going to bed to protect the fetus from continuous 
exposure to nicotine. While nicotine passes from mother to child in breast milk, 
it is unlikely to be dangerous.105 Women who continue to smoke after the birth 
should be encouraged to breastfeed their babies. Women who are unable to 
quit smoking completely can be given strategies to minimise exposure to the 
baby of secondhand smoke.
Neither of the two prescription medicines for smoking cessation in Australia, 
varenicline and bupropion, has been shown to be effective or safe for smoking 
cessation treatment in pregnant and breastfeeding smokers and they are 
not recommended. If a woman becomes pregnant while taking either agent, 
treatment should be ceased, and, if she agrees, reporting her pregnancy 
outcome to health authorities and the manufacturer may over time help better 
understand any risk.
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All woman of child bearing age should be encouraged to stop smoking. Smoking 
cessation policy hopes to minimise the effects of smoking among all women – 
long term reduction in nicotine exposure during pregnancy can be achieved only 
by encouraging adolescent girls and young women not to start smoking.23 It is 
also important to advise partners of pregnant women not to smoke around them 
and to encourage them to quit, as this can improve quit rates.
Recommended smoking cessation treatment
• Pregnant women should be encouraged to stop smoking completely
• They should be offered intense support and proactive telephone counselling 
• Self help material can supplement advice and support 
•  If these interventions are not successful, health professionals should 
consider NRT, after clear explanation of the risks involved
•  Because of the uncertainty of the safety of NRT used during pregnancy, 
pregnant women wishing to quit using NRT should be monitored by a 
suitably qualified health professional
• Those who do quit should be supported to stay non-smokers long term.
Evidence
There is currently a lack of evidence on the safety of pharmacotherapy in 
pregnancy, but international guidelines recommend use of NRT in certain 
circumstances. Level V
Recommendation
Use of NRT should be considered when a pregnant woman is otherwise 
unable to quit. Intermittent NRT is preferred to patches (lower total daily 
nicotine dose). Strength C
Adolescents and young people
It is estimated that more than 80% of smokers become addicted to nicotine as 
teenagers. Adolescence is the primary time when cigarette smoking is initiated 
and transition from experimentation to dependence occurs. In Australia in 2010, 
3.8% of teenagers (12–17 year olds) smoked tobacco and 2.5% smoked daily.1 
Although men were generally more likely to be daily smokers than women, in 
the 12–17 years age group, young women were more likely to be daily smokers 
(3.2%) than young men (1.8%). However, young Australians aged 12–17 years 
were the age group least likely to smoke daily (2.5%).1 One third of teenagers who 
become regular smokers will eventually die prematurely from smoking related 
diseases.171
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The reasons young people commence smoking are varied and relate to 
social and parental norms, advertising, peer influence, parental smoking, 
weight control and curiosity. Recruitment and retention of adolescents in 
formal smoking cessation programs are difficult and are a major determinant 
of intervention targeting young people.6 Computer and internet cessation 
programs are potential vehicles for programs aimed at young people, but as yet 
there is no clear evidence on efficacy. 
Many adolescent anti-tobacco programs focus on preventing teenagers from 
starting to smoke, rather than quitting. These programs are largely ineffective. 
Likewise, there is insufficient evidence to show that smoking cessation 
programs to help teenagers who already smoke to quit are effective.172 There 
are also few studies with evidence about the effectiveness of pharmacological 
interventions for adolescent smokers. 
Some quitting medications can be used by younger smokers. NRT can be 
offered if the smoker is nicotine dependent and ready to quit. Although NRT 
has been shown to be safe in adolescents, there is little evidence that these 
medications and bupropion or varenicline are effective in promoting long term 
quitting in adolescent smokers. The majority of studies included an intensive 
counselling component (6 or more sessions).10
Recommended smoking cessation treatment
• Counselling is considered to be vital in this age group
• Health professionals should ask about smoking and provide a strong anti-
smoking message
• NRT is recommended to adolescents only with precautions. The health 
professional should assess the nicotine dependence, motivation to quit and 
willingness to accept counselling before recommending NRT
• Bupropion and varenicline are not approved for use by smokers under 18 
years of age.
People with mental illness
Smoking in people with mental health problems is common. The smoking 
rate of the Australian population is just over 15%,1 but for people with a mental 
health problem the rate is about 32%.21 In some cases, such as for people with 
schizophrenia, the rate is up to 62%.173 Although there is a belief that nicotine 
may modify some negative psychotic symptoms, such as lack of motivation 
and energy, and may decrease positive psychotic symptoms, such as auditory 
hallucinations, the belief is not supported by clinical evidence174,175 and nicotine 
has proved ineffective as an adjunctive treatment for mental disorders.176 
People with mental illness such as schizophrenia, depression, bipolar disorder 
and anxiety often experience physical, financial and social disadvantages 
because of their illness.177,178 Many people with mental illness who smoke wish 
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to quit. Actively encouraging and assisting smoking reduction and cessation 
are important to improve their quality of life. Tobacco smoking can also interfere 
with the medications taken for schizophrenia and depression, and the doses of 
some medications may need to be increased or decreased. 
Treating tobacco dependence is a worthwhile intervention for people with severe 
mental illness and may be just as effective as for the general population. In 
people with stable psychiatric conditions it should not worsen mental health.178,179 
Health professionals should offer people with a mental illness smoking cessation 
interventions that have been shown to be effective in the general population.7 
Mental illness is not a contraindication to stopping smoking but the illness and its 
treatment need to be monitored carefully during smoking cessation.180–182 
Recommended smoking cessation treatment
• Intensive smoking cessation counselling and close follow up are important 
in this group
• NRT is safe and effective for people with a mental illness 
• Consultation with a psychiatrist may be considered for advice on use of 
medicines for smoking cessation in people with significant mental illness
• Bupropion may not be suitable for people with a history of seizures, people 
with a history of anorexia or bulimia and people using other antidepressants. 
Caution is needed if there is concomitant use of bupropion with drugs such 
as tricyclic antidepressants and selective serotonin reuptake inhibitors. 
These drugs should be initiated at the lower end of the dosage range 
while a smoker is taking bupropion. In the more common situation that 
bupropion is initiated for a person already taking such antidepressants 
then the dose of tricyclic, or selective serotonin reuptake inhibitor, may 
need to be decreased. Bupropion should not be used in patients taking 
monoamine oxidase inhibitors (MAOIs) including moclobemide. A 14 
day washout is recommended between completing MAOIs and starting 
bupropion. Consultation with a psychiatrist may be considered for advice on 
coprescribing bupropion with other antidepressants
• There is limited evidence of the safety and efficacy of varenicline in people 
with significant psychiatric illness. Varenicline helps with withdrawal 
symptoms and takes away the pleasure of smoking. There have been 
reports of depressed mood, suicidal ideation and changes in emotion 
and behaviour using this product; so far these reports have not been 
substantiated.86 There is recent evidence from a study of drug adverse 
events that these effects are more common with varenicline than NRT.111 
Prescribers should ask patients to report any mood or behaviour changes. 
Smokers should be advised to stop taking varenicline at the first sign of any 
of these symptoms. The findings from a small pilot study show that when 
used with appropriate clinical monitoring, varenicline can help smoking 
cessation in people with schizophrenia.180
50 Healthy Profession. Healthy Australia.
The RACGP 
Supporting smoking cessation: a guide for health professionals
People with substance use problems
Tobacco smoking is common in people with other drug use such as alcohol, 
cannabis and opiate dependence. Cannabis and tobacco are often used 
together as a way of smoking cannabis. As rates of cigarette smoking decline, it 
is now more common for cannabis dependence to lead to tobacco dependence 
than was previously the case.183 Smoking cessation has not been a major part 
of clinical interventions with these people as the attention is usually focussed 
on the alcohol or illicit drug use. There is good evidence that smoking cessation 
can enhance short term abstinence, rather than compromise the outcome of 
drug and alcohol treatments.184 
There is evidence that people with alcohol dependence can have similar 
success rates in smoking cessation to the general population,185 although binge 
drinking is a risk factor for relapse.186 There is also evidence that continued 
smoking adversely affects treatment for cannabis dependence. Success in 
smoking cessation for people with opiate dependence is lower than the general 
population. Monitoring and support are needed for smoking cessation in 
people with substance use problems who may benefit from the involvement of 
other health professionals, such as a drug and alcohol counsellor or intensive 
counselling from Quitline.
Recommended smoking cessation treatment
• Health professionals should offer encouragement, motivation, advice and 
counselling to these people
• NRT is effective for quit attempts
• Bupropion should be monitored carefully when used concurrently with 
alcohol use
• Varenicline10 – there have been some reports of depressed mood, suicidal 
ideation and changes in emotion and behaviour using this product – but 
so far these reports have not been substantiated.91 Prescribers should ask 
patients to report any mood or behaviour changes. Smokers should be 
advised to stop taking varenicline at the first sign of any of these symptoms.
Prisoners 
The prevalence of smoking in the prison population is far higher than among 
the general population, and tobacco use is accepted as the norm in prison 
life.187 There is a strong association between smoking tobacco and social 
disadvantage and those from low socioeconomic groups are over represented 
in the prison system, for example, indigenous people, drug users, the less 
educated and those suffering mental illness. Each of these factors predicts 
higher smoking rates.16
Motivation to quit smoking is high in the prison population. In New South Wales 
prisons where smoking rates were 80% in 2006, 52% of inmates had attempted 
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to reduce or quit smoking and 58% had plans to quit.187 In some Australian 
states, smoking cessation groups and telephone support from Quitline have 
been provided in some prisons. In Victoria, NRT is available free of charge 
through a levy fund, which has operated in Victoria’s public prisons since 
1993. Some prisons also sell NRT patches through prison canteens.16 In New 
Zealand, smokefree prisons have been successfully implemented, including 
freely available NRT for prisoners and staff who smoke. 
Smoking cessation programs conducted in prisons should address prison 
specific difficulties by including items such as a stressor pack to assist prisoners 
during transfer to other prisons and court appearances.42 Support programs 
should also discuss how to prevent relapse on release from prison.
Recommended smoking cessation treatment
• Health professionals should take every opportunity to offer advice to quit 
• Provide pharmacotherapy (NRT, bupropion, varenicline)
• Proactive telephone counselling (Quitline 13 7848)
• Close follow up.
People with smoking related diseases
There is clear evidence that people with a smoking related disease or with other 
risk factors for cardiovascular disease such as diabetes, lipid disorders and 
hypertension who continue to smoke greatly increase their risk of further illness. 
It is important to target this population of smokers for smoking cessation, given 
the role that smoking plays in exacerbating these conditions.10 For example, 
second heart attacks are more common among cardiac patients if they 
continue to smoke and people with successfully treated cancers who continue 
to smoke are at increased risk of a second cancer.188 People with diabetes who 
smoke increase their risk of cardiovascular disease, peripheral vascular disease, 
progression of neuropathy and nephropathy. Smoking also increases the risk 
associated with hospitalisation for surgery. Quitting smoking after a heart attack 
or cardiac surgery can decrease a person’s risk of death by at least one third.188
Smoking has an ongoing impact on patients with chronic airways disease, 
such as COPD and asthma. There is a clear relationship between continued 
smoking and progression of COPD.6 Smoking in those with COPD is associated 
with a faster decline in lung function, an increase in symptoms – as well as an 
increased risk for respiratory tract infection and hospitalisation.189,190 In people 
with asthma, smoking further impairs lung function, increases symptoms and 
impairs the effectiveness of treatment.191,192 First line management of all smokers 
with asthma should always be strong encouragement to quit.
Many studies have found significant associations between cigarette smoking 
and the development of diabetes, impaired glycaemic control and diabetic 
complications.23 Smokers with type 2 diabetes need a larger insulin dose 
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to achieve metabolic control similar to that in patients who do not smoke.193 
Smoking is associated with increased risk of type 2 diabetes in both men and 
women.194–196 Health professionals should be aware that smoking cessation is 
a crucial aspect of diabetes care for adequate glycaemic control and limiting 
development of complications.23  
There is strong evidence that people with cardiovascular disease are highly 
motivated to quit smoking and success rates can be high, especially where 
they understand the link between their health problem and their smoking. It is 
recommended that smoking cessation programs are integrated into the routine 
chronic disease management programs for this population of smokers. High 
intensity behavioural interventions are effective. There is some evidence that 
adding NRT, bupropion or varenicline to intensive counselling is effective in this 
group.197–199
Recommended smoking cessation treatment
• Use of the medical condition as an opportunity to integrate quitting into a 
management program
• Intensive cognitive behavioural counselling may be worthwhile      
• Varenicline or NRT 
• Bupropion for cardiovascular disease and COPD
• If diabetes is well controlled with insulin or oral hypoglycaemic medicine, 
150 mg once daily of bupropion can be prescribed. If the condition is poorly 
controlled, NRT should be considered.13
Evidence
Continued smoking is a major factor in the recurrence or increasing severity of 
smoking related diseases. Overwhelming epidemiological evidence
Recommendation
Smoking cessation should be a major focus of the management of people with 
smoking related diseases Strength A 
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Secondhand smoke, or passive smoking, can affect the health of people 
who do not smoke. There is clear evidence of the harms of exposure to 
environmental tobacco smoke in pregnancy, to children (higher rates of 
respiratory and middle ear infections, meningococcal infections and asthma) 
and adults (increased risk of lung cancer and coronary heart disease). The 
evidence for the health effects of secondhand smoking has been summarised 
by a number of health authorities including the National Health and Medical 
Research Council.11,84,127,200 The US Department of Health and Human Services 
has stated that there is no safe level of exposure to tobacco smoke. Any 
exposure to tobacco smoke – even an occasional cigarette or exposure to 
secondhand smoke – is harmful,23 especially to children.201
There is a lack of evidence on the effectiveness of counselling non-smokers to 
limit exposure to tobacco smoke. There is evidence that providing information 
to parents on the harms of exposing children to environmental tobacco smoke 
can reduce their exposure.99 Due to the evidence of harms from exposure, non-
smokers, especially parents of babies and young children and pregnant women, 
should be strongly advised to limit exposure to tobacco smoke. Smoking 
parents should be encouraged not to smoke in the house, or in a confined 
space such as a motor vehicle at any time.
Evidence
Introducing smoking restrictions into the home can assist quitting smoking 
successfully. Level IV
Recommendation
People attempting to quit should be advised to ban, or restrict smoking by 
others in their homes. Strength C
Secondhand smoke
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Resources for health professionals
RACGP publications (including Smoking cessation guidelines for Australian health 
professionals) 
www.racgp.org.au/guidelines 
www.racgp.org.au/guidelines/smokingcessation
Quit Victoria 
www.quit.org.au
Federal, state and territory initiatives (provides links to other tobacco control sites)  
www.quitnow.info.au
US Department of Health and Human Services Clinical Practice Guideline Treating 
Tobacco Use and Dependence. 2008 Update www.surgeongeneral.gov/tobacco/
treating_tobacco_use08.pdf
New Zealand Smoking Cessation Guidelines 
www.health.govt.nz/publications/new-zealand-smoking-cessation-guidelines
World Health Organization GlobaLink. Global tobacco control. International 
Tobacco Control Network managed by the International Union against Cancer. 
www.globalink.org
World Health Organization site on tobacco 
www.who.int/tobacco/en
Treatobacco.net is produced and maintained by the Society for Research on 
Nicotine and Tobacco, in association with the World Bank, Centers for Disease 
Control and Prevention, the World Health Organization, the Cochrane Group 
and a panel of international experts. This site provides evidence based data and 
practical support for the treatment of tobacco dependence. It is aimed at health 
professionals and policy makers. 
www.treatobacco.net
Action on Smoking and Health (Australia) is a not for profit organisation, which 
aims to reduce the harmful effect of tobacco use by advocating a comprehensive 
tobacco control, strategy at national, state and local levels. 
www.ashaust.org.au
Resilience Education and Drug Education. This website from the Australian 
Government Department of Education, Employment and Workplace Relations 
contains a comprehensive database of resources, policies and materials for drug 
education.  
www.redi.gov.au
SANE is an advocacy organisation to assist people with mental illness. SANE has 
developed a number of resources on mental illness and smoking such as the 
SmokeFree Zone resource pack and the Smokefree Kit for health professionals.  
www.sane.org
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Australian Association of Smoking Cessation Professionals (AASCP) for referral to a 
tobacco treatment specialist.  
www.aascp.org.au
Support programs offered by pharmaceutical companies such as:
–  www.nicabate.com.au/support-tools (NRT, GlaxoSmithKline Consumer Healthcare)
– ActiveStop: www.nicorette.com.au (NRT, Johnson & Johnson Pacific)
– My Time to Quit: www.mytimetoquit.com.au (varenicline, Pfizer).
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Summary of evidence and recommendations 
1.   Evidence Smoking cessation advice from health professionals is effective 
in increasing quit rates. The major effect is to help motivate a quit attempt. 
Level I
  All health professionals can be effective in providing smoking cessation 
advice. Level I
  Recommendation All smokers should be offered brief advice to quit. 
Strength A
2.   Evidence Instituting a system designed to identify and document tobacco 
use almost doubles the rate of health professional intervention and results 
in higher rates of cessation. Level II
  Recommendation A system for identifying all smokers and documenting 
tobacco use should be used in every practice or healthcare service. 
Strength A
3.   Evidence Factors consistently associated with higher abstinence rates 
are high motivation, readiness to quit, moderate to high self-efficacy and 
supportive social networks. Level III
  Recommendation Assessment of readiness to quit is a valuable step in 
planning treatment. Strength C
4.   Evidence Brief smoking cessation advice from health professionals 
delivered opportunistically during routine consultations has a modest effect 
size, but substantial potential public health benefit. Level I
  Recommendation Offer brief cessation advice in routine consultations 
and appointments whenever possible (at least annually). Strength A
5.   Evidence Telephone callback counselling services are effective in assisting 
cessation for smokers who are ready to quit. Level II
  Recommendation Referral to such services should be considered for this 
group of smokers. Strength A
6.  Evidence Follow up is effective in increasing quit rates. Level I
  Recommendation All smokers attempting to quit should be offered follow 
up. Strength A
7.   Evidence Pharmacotherapy with nicotine replacement therapy, varenicline 
or bupropion is an effective aid to assisting motivated smokers to quit. 
Level I
  Recommendation In the absence of contraindications, pharmacotherapy 
should be offered to all motivated smokers who have evidence of nicotine 
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dependence. Choice of pharmacotherapy is based on clinical suitability 
and patient choice. Strength A
8.   Evidence Nicotine transdermal patch, nicotine gum and nicotine inhaler all 
increase quit rates by 50–70% at 5–12 months compared with placebo and 
regardless of the setting. Level I
  There is no evidence of increased risk for use of NRT in people with stable 
cardiovascular disease. Level IIThere is no evidence of an association 
between use of nicotine patch and acute cardiac events. Level II
  There is a lack of evidence on the safety of NRT in pregnancy and when 
breastfeeding, but international expert guidelines recommend that it should 
be used in certain circumstances. Level V
  In more dependent smokers, combinations of different forms of NRT (eg. 
patch plus gum) are more effective than one form alone. Level II
  Recommendations NRT should be recommended to nicotine dependent 
smokers. There is no significant difference in effectiveness of different 
forms of NRT in achieving cessation, so choice of product depends on 
clinical and personal considerations. Strength A
  NRT is safe to use in patients with stable cardiovascular disease. Strength A
  NRT should be used with caution in patients who have had a recent 
myocardial infarction, unstable angina, severe arrhythmias or recent 
cerebrovascular events. Strength C
  Pharmacotherapy with NRT should be considered when a pregnant 
woman is otherwise unable to quit, and when the likelihood and benefits of 
cessation outweigh the risks of using NRT. Level C
  Combination NRT should be offered if patients are unable to remain 
abstinent or continue to experience withdrawal symptoms using one type 
of therapy. Strength A
9.  Evidence Varenicline is an efficacious smoking cessation treatment. Level I
  Recommendation Varenicline should be recommended to smokers who 
have been assessed as clinically suitable for this medication and should be 
provided in combination with counselling. Strength A
10.   Evidence Bupropion sustained release is an efficacious smoking cessation 
treatment. Level I
  Recommendation Bupropion sustained release should be recommended 
to smokers who have been assessed as clinically suitable for this 
medication and provided in combination with counselling. Strength A
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11.   Evidence Nortriptyline is an efficacious smoking cessation treatment in 
people with and without a history of depression. Level II
  Recommendation Nortriptyline should only be considered as a second-
line agent due to its adverse effects profile. Strength B
12.  Evidence There is no significant effect of acupuncture or hypnotherapy in 
smoking cessation. Level I
  Recommendation On the evidence available acupuncture and 
hypnotherapy are not recommended as aids to smoking cessation. 
Strength A
13.  Evidence There is currently a lack of evidence on the safety of 
pharmacotherapy in pregnancy, but international guidelines recommend 
use of NRT in certain circumstances. Level V
  Recommendation Use of NRT should be considered when a pregnant 
woman is otherwise unable to quit. Intermittent NRT is preferred to patches 
(lower total daily nicotine dose). Strength C
14.  Evidence Continued smoking is a major factor in the recurrence 
or increasing severity of smoking related diseases. Overwhelming 
epidemiological evidence.
  Recommendation Smoking cessation should be a major focus of the 
management of people with smoking related diseases. Strength A 
15.  Evidence Introducing smoking restrictions into the home can assist 
quitting smoking successfully. Level IV
  Recommendation People attempting to quit should be advised to ban or 
restrict smoking by others in their homes. Strength C
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  Last	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  use	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  Quitline	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Address:	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Phone:	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Fax:	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Health	  professional:	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  details	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  organisation.	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Smoking	  status	  
	  	  	  	  	  Daily	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Weekly	   	   Less	  than	  weekly	   	   Number	  per	  day	  
What	  stage	  is	  your	  patient	  at	  with	  quitting?	  
	  	  	  	  	  Not	  ready	  (not	  currently	  thinking	  of	  quitting)	   	   Unsure	  (thinking	  about	  quitting	  within	  6	  months)	  
	  	  	  	  	  Ready	  (planning	  to	  quit	  within	  1	  month)	   	   Recent	  quitter	  (within	  the	  last	  year)	  
Use	  of	  medication?	  
	   Currently	  using/	  planning	  to	  use	  Bupropion	  Hydrochloride	  (Zyban)	  
	   Currently	  using/	  planning	  to	  use	  Varenicline	  (Champix)	  
	   Currently	  using/	  planning	  to	  use	  nicotine	  patches/	  gum/	  inhaler/	  lozenge/	  micotab	  
What	  are	  the	  patient’s	  health	  issues	  relevant	  to	  Quitline	  counsellors?	  
	   Heart/lung	  disease	   	   Respiratory	  disease	   	   Diabetes	   	   Depression	  	   	   Anxiety	   	  
	   Psychosis	   	   	   Pregnancy	   	   	   Other	  –	  please	  specify	  _______________________________________	  
Please	  note	  
The	  interaction	  of	  chemicals	  in	  cigarettes	  and	  some	  medications	  e.g.	  insulin,	  some	  antidepressants/antipsychotics,	  and	  the	  interplay	  between	  the	  
chemicals	  and	  some	  symptoms	  can	  mean	  some	  smokers	  need	  monitoring	  of	  drug	  levels	  and	  symptoms	  by	  their	  GP	  through	  the	  quitting	  process.	  
Health	  professional	  is	  monitoring	  
the	  above	   	   	  
	   Yes	  
	   No	  
_______________________________	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  __________________________________	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  __	  __/__	  __/__	  __	  
Health	  professional	  signature	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Patient’s	  signature	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Date	  
For	  use	  by	  Quitline	  staff	  
Quitline	  confirmation	  of	  action	  on	  referral	  date:	  __	  __/__	  __/__	  __,	  your	  referral	  for	  ____________________________________________________	  
has	  been	  received	  by	  Quitline	  on	  __	  __/__	  __/__	  __	  ,	  a	  call	  back	  time	  has	  been	  organised	  for	  __	  __/__	  __/__	  __.	  
	  
Referral	  feedback	  sent	  back	  to	  _____________________________________	  (referrer	  /	  GP	  name)	  on	  __	  __/__	  __/__	  __,	  
	  
	  
	  
www.quitnow.info.au	  
The	  Quitline	  is	  answered	  24	  hours	  a	  day.	  Counselling	  is	  available	  with	  hours	  varying	  dependent	  on	  state	  or	  territory.	  Specialist	  staff	  will	  call	  your	  referred	  patient	  back	  at	  
an	  agreed	  time	  within	  the	  next	  week	  to	  provide	  information,	  support	  and	  advice	  on	  smoking	  cessation.	  
I	  consent	  to	  this	  information	  being	  faxed	  to	  Quitline	  and	  for	  Quitline	  staff	  to	  call	  me	  at	  a	  time	  that	  
I	  have	  suggested	  on	  this	  form.	  I	  understand	  that	  persons	  within	  the	  organisation	  with	  access	  to	  
the	  fax	  machine,	  who	  may	  not	  be	  Quitline	  staff,	  might	  view	  this	  form.	  I	  understand	  that	  in	  
Queensland	  my	  telephone	  calls	  will	  be	  recorded	  for	  the	  purposes	  of	  quality	  monitoring	  and	  
service	  improvement.	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Effect of smoking abstinence on medications
Smoking tobacco can alter the metabolism of a number of medicines. This is 
primarily due to substances in tobacco smoke, such as hydrocarbons or tar-like 
products that cause induction (speeding up) of some liver enzymes (CYP 1A2, 
in particular). Therefore, medicines metabolised by these enzymes are broken 
down faster and can result in reduced concentrations in the blood (see table 
below). When a person stops smoking, the enzyme activity returns to normal 
(slows down), which may result in increased levels of these medicines in the 
blood. Monitoring and dosage reduction may often be required.
Smoking affects the following medications
Medication Effect of smoking
Caffeine  Increased clearance (by 56%)
Chlorpromazine  Decreased serum concentrations (by 24%)
Clozapine  Decreased plasma concentrations (by 28%)
Estradiol  Possibly anti-estrogenic effects
Flecainide  Increased clearance (by 61%)
Fluvoxamine  Decreased plasma concentrations (by 47%)
Haloperidol  Decreased serum concentrations (by 70%)
Heparin  Increased clearance
Imipramine  Decreased serum concentrations
Insulin   Decreased subcutaneous absorption due to poor 
peripheral blood flow
Lidocaine  Decreased oral bioavailability
Olanzapine  Increased clearance (by 98%)
Propranolol  Increased oral clearance (by 77%)
Tacrine  Decreased mean plasma concentrations (3-fold)
Theophylline   Increased metabolic clearance (by 58 to 100%); within 7 days 
of smoking cessation, theophylline clearance falls by 35%
Warfarin   Decreased plasma concentrations (by 13%). No effect on 
prothrombin time
Stopping smoking can result in the opposite of the effects noted above. 
Healthcare workers should be aware of the potential for increased blood levels 
of some of these medicines when smoking is stopped. Blood levels of some 
(eg. clozapine, theophyline) may need to be monitored.
Used with permission from: Ministry of Health. New Zealand Smoking Cessation Guidelines.  
Wellington: Ministry of Health. 2007
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Smoking/smoking cessation does not affect the following 
medications202
• Benzodiazepines (diazepam, lorazepam, midazolam, chlordiazepoxide)
• Bupropion
• Ethinyl estradiol 
• Glucocorticoids (prednisone, prednisolone, dexamethasone)
• Paracetamol
• Quinidine
Effects of smoking/smoking cessation on the following medication  
is unclear
• Nortriptyline
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Notes
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